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ENTRY AND REPLICATION OF NEGATIVE-STRAND RNA VIRUSES 
 
Hendra virus (HeV) and human metapneumovirus (HMPV) are negative- 
sense, singled-stranded RNA viruses. The paramyxovirus HeV is classified as a 
biosafety level 4 pathogen due to its high fatality rate and the lack of a human 
vaccine or antiviral treatment. HMPV is a widespread pneumovirus that causes 
respiratory tract infections which are particularly dangerous for young children, 
immunocompromised individuals, and the elderly. Like HeV, no vaccines or 
therapies are available to combat HMPV infections. These viruses fuse their lipid 
envelopes with a cell to initiate infection. Blocking cell entry is a promising 
approach for antiviral development, and many vaccines are designed based on the 
envelope protein responsible for fusion. Following fusion, the coated genome and 
its associated proteins are released into the cytoplasm for replication and 
transcription. HMPV and other negative-strand viruses form membrane-less 
inclusion bodies (IBs) which act as viral factories to promote these processes. 
HMPV IBs represent another promising target for developing new antivirals since 
they house the replication machinery. Viral fusion and cytoplasmic replication are 
ubiquitous to most negative-strand viruses and are addressed in this work through 
analysis of HeV and HMPV. 
HeV utilizes a trimeric fusion protein (F) within its lipid bilayer to mediate 
membrane merger with a cell for entry. Previous HeV F studies showed that 
transmembrane domain (TMD) interactions are important for stabilizing the 
prefusion conformation of the protein prior to triggering. Thus, the current model 
for HeV F fusion suggests that modulation of TMD interactions is critical for 
initiation and completion of conformational changes that drive membrane fusion. 
HeV F constructs (T483C/V484C, V484C/N485C, and N485C/P486C) were 
generated with double cysteine substitutions near the N-terminal region of the TMD 
to study the effect of altered flexibility in this region. Oligomeric analysis showed 
that the double cysteine substitutions successfully promoted intersubunit disulfide 
bond formation in HeV F. Subsequent fusion assays indicated that the introduction 
of disulfide bonds in the mutants prohibited fusion events, likely due to the limited 
flexibility in the TMD. Further testing confirmed that T483C/V484C and 
V484C/N485C were expressed at the cell surface at levels that would allow for 
fusion. Attempts to restore fusion with a reducing agent were unsuccessful, 
suggesting that the introduced disulfide bonds were likely buried in the membrane. 
Conformational analysis showed that T483C/V484C and V484C/N485C were able 
to bind a prefusion conformation-specific antibody prior to cell disruption, indicating 
that the introduced disulfide bonds did not significantly affect protein folding. This 
study strengthens the current model for HeV fusion and provides important insight 
for understanding the basic mechanisms of membrane fusion for negative-strand 
RNA viruses. 
HMPV IBs are dynamic structures required for efficient replication and 
transcription. The minimum components needed to form IB-like structures in cells 
are the nucleoprotein (N), which coats the RNA genome, and the tetrameric 
phosphoprotein (P), which acts as a cofactor to the polymerase. HMPV P binds to 
two versions of N protein in infected cells: C-terminal P residues interact with 
oligomeric, RNA-bound N (N-RNA), and N-terminal P residues interact with 
monomeric N (N0) to maintain a pool of protein to encapsidate new RNA. Recent 
work on other negative-strand viruses has shown that IBs are liquid-like organelles 
formed via liquid-liquid phase separation (LLPS). Recombinant versions of HMPV 
N and P proteins were purified to analyze the interactions required to drive LLPS 
in vitro. Purified HMPV P was shown to form liquid droplets in the absence of other 
protein binding partners, suggesting that it functions as a scaffold to recruit client 
proteins to IBs. HMPV P recruited a monomeric N protein construct, N0-P, to liquid 
droplets. In addition, HMPV P incorporated N-RNA into liquid droplets, though N- 
RNA formed aggregates independently. These findings support that HMPV P acts 
as a scaffold protein to mediate multivalent interactions with monomeric and 
oligomeric HMPV N to promote phase separation of IBs. Collectively, the work 
presented here provides important insight into the processes of viral entry, 
replication, and IB formation for negative-strand RNA viruses. 
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Chapter 1: Background and Introduction 
 
 
The Mononegavirales order 
 
The Mononegavirales order was created in 1991 to classify three families 
of viruses. As of 2018, the order now includes eight families: Bornaviridae, 
Filoviridae, Mymonaviridae, Nyamiviridae, Paramyxoviridae, Pneumoviridae, 
Rhabdoviridae, and Sunviridae (1). Four of these families are recognized for their 
role in human disease: Filoviridae, Paramyxoviridae, Pneumoviridae, and 
Rhabdoviridae (2). All viruses within these families possess a lipid bilayer envelope 
that is derived from the host cell. The envelope includes membrane glycoproteins 
that are responsible for binding to a cell and fusing the envelope with the target 
cell membrane. Fusion of the membranes allows for the release of the viral 
genome and its associated proteins into the cell cytoplasm. The Mononegavirales 
viruses possess nonsegmented genomes, meaning that the genetic material is 
included on one strand of nucleic acid. Additionally, the genomes are made of 
negative-sense RNA, so the viruses must deliver the genome with proteins needed 
for replication and transcription into the target cell to initiate infection (1). The 
genome is flanked by a 3’ leader sequence and 5’ trailer sequence that help 
regulate replication and transcription. Five to ten genes are encoded by the 
genome, and transcription of the genes generates viral mRNAs that are capped 
and polyadenylated. The viral mRNAs are translated and the genome is replicated 
so that new viral particles can be assembled and released, often through budding 
events at the cell plasma membrane. The results reported in later chapters of this 
dissertation describe viruses from the Paramyxoviridae and Pneumoviridae 
families. Specifically, this work focuses on fusion events related to viral entry and 
mechanisms involved in viral replication. Though this work analyzes two viruses to 
explore these life cycle steps, the findings are applicable to many viruses 
throughout the Mononegavirales order. Understanding basic mechanisms in the 
life cycle of negative-sense, single-stranded RNA viruses is critical for the 




The Paramyxoviridae family contains numerous members, including 
several human pathogens of medical significance, such as measles virus (MeV), 
mumps virus (MuV), and the parainfluenza viruses (PIVs). The family also includes 
the zoonotic pathogens Hendra virus (HeV) and Nipah virus (NiV) which were 
discovered in 1994 and 1999, respectively, after spillovers occurred in humans (3). 
Members of the Paramyxoviridae family such as Sendai virus and Newcastle 
disease virus are known to infect other animal species (4). Viruses within this 
family transmit via a horizontal pathway, meaning that they spread between 
members of the same generation rather than from mother to offspring, and they 
typically utilize airborne routes (5). 
Paramyxovirus particles are generally 150 to 500 nm in diameter, and they 
are pleomorphic, though most have a spherical shape (5). The viral lipid bilayer 
encloses the RNA genome which is coated in nucleoprotein (N) to form a helical 
nucleocapsid. Genomes for paramyxoviruses range from 15 to 19 kilobases. The 
genome codes for six to ten gene products, including two transmembrane 
glycoproteins found in the viral lipid bilayer. These transmembrane proteins allow 
the virus to attach and fuse with target cells to initiate the viral life cycle (4). Some 
paramyxoviruses also encode a third membrane protein known as the small 
hydrophobic protein (SH), but the function of this protein is less clear. The SH 
protein is reported to inhibit TNF-alpha signaling for two rubulaviruses within the 
Paramyxoviridae family (6). Once the virus fuses with a target cell, transcription of 
the genome occurs in the cytoplasm. The viral phosphoprotein (P) and RNA- 
dependent RNA polymerase use the N-encapsidated, negative-sense genome as 
a template to encode mRNAs that are translated by host cell machinery to produce 
viral proteins. Additionally, the negative-sense RNA genome is used as a template 
to produce positive-sense antigenome. In turn, the positive-sense antigenome is 
replicated to make negative-sense genomic copies that are coated in N protein 
and transported to the plasma membrane for assembly with other viral 




HeV was identified in 1994 after an outbreak in Brisbane, Australia that led 
to the death of 14 horses and one human (7, 8). Horses infected with HeV typically 
experience acute respiratory symptoms and high fevers (9). In humans, HeV 
causes flu-like respiratory symptoms that can progress to severe pneumonia, and 
infection is also associated with encephalitis, leading to symptoms such as 
confusion and headaches (7, 10). All human cases of HeV have been linked to 
close contact with infected horses (11). The initial outbreak and subsequent cases 
in Australia culminated in an 89 percent fatality rate in horses and a 57 percent 
fatality rate in humans (10). Since HeV is designated as a biosafety level 4 
pathogen, work with live HeV is restricted to specialized biocontainment facilities 
(12). The life cycle of HeV initiates with an attachment and fusion event, in which 
the viral membrane merges with the target cell membrane (FIG 1.1). The coated 
genome is released into the target cell where it undergoes replication and 
transcription in the cytoplasm. The viral mRNAs are translated into protein and 
assembled with newly synthesized viral genome at the cell surface. The virus 
acquires its membrane, studded with viral proteins, from the host as it buds from 
the surface. 
Further research into the causes of the HeV outbreak led to the identification 
of Australian flying fox fruit bats of the Pteropus genus as the natural reservoir for 
the zoonotic virus. These bats are nocturnal foragers, and they are abundant in 
urban areas within eastern Australia where they find reliable food sources (9). The 
four flying fox species of bats native to Australia are all seropositive for HeV 
antibodies (12). A model was proposed that horses were exposed to HeV by eating 
fruit contaminated with infected bat urine (10). Horse-to-horse transmission of 
infection has been observed in subsequent outbreaks (9). Horses have served as 
an intermediate host to amplify the virus and pass the infection to humans. Though 
a horse vaccine against HeV became available in 2012, there are currently no 
approved vaccines or treatments to protect humans (11). 
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HeV is closely related to the paramyxovirus NiV, which caused an outbreak 
of encephalitic disease in Malaysia in 1999. During the outbreak, 265 encephalitic 
cases were confirmed in patients, and 105 deaths were reported, leading to a 
fatality rate of approximately 40 percent (13). Since the zoonotic HeV and NiV 
showed many differences from other members of the Paramyxoviridae family, the 
Henipavirus genus was created in 2000 to categorize these pathogens (1). 
Research into the source of the NiV outbreak showed that the virus was 
transmitted from bats to pigs before spilling into humans (3). Deadly NiV outbreaks 
have also occurred in Bangladesh, Singapore, and India. Additionally, human-to- 
human transmission of NiV was observed in Bangladesh and India (14). Like HeV, 
there are no approved vaccines or therapies to combat future NiV disease 
outbreaks in humans. 
Scientists have also discovered a non-pathogenic henipavirus, known as 
Cedar virus (CedPV), which was isolated from the urine of Australian fruit bats 
(15). Since studies of HeV and NiV are limited due to their biosafety classification, 
research on live CedPV will be beneficial for elucidating the infectious mechanisms 
of henipaviruses. The current COVID-19 pandemic highlights the importance of 
studying the life cycle of emergent respiratory pathogens like HeV and NiV. Severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID- 
19, is a positive-strand RNA virus with a genome of approximately 30 kilobases. 
Some coronavirus replication complexes have been shown to possess 
proofreading ability, which is important for controlling the mutation rate during 
replication of the large RNA genomes (16). When mutations do occur, they may 
increase the likelihood of spillover into a different species. Like HeV and NiV, 
SARS-CoV-2 is a zoonotic virus that is thought to have originated in bats before 
spilling into humans, and it primarily transmits via respiratory droplets (17). The 
high quantity of asymptomatic SARS-CoV-2 infections has contributed to the 
worldwide spread of disease. Although the henipaviruses and coronaviruses are 
categorized within different phylogenetic orders, similarities in their origin and 
transmission routes suggest that further research is needed to analyze the 
emergence of respiratory pathogens. Understanding the processes by which HeV 
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and NiV initiate infection, replicate, and spread may contribute to discoveries to 
prevent widespread outbreaks of newly emerged RNA viruses. Specifically, 
research into HeV fusion events is critical for the development of novel therapies 
and vaccines that may protect human populations from deadly infections. 
Paramyxovirus surface glycoproteins 
 
Paramyxoviruses possess attachment proteins (H, HN, or G) and fusion 
proteins (F) that are located on the surface of the virus. The attachment proteins 
are homotetrameric type II integral membrane proteins that bind to specific 
receptors on target cells (4). They consist of a globular receptor binding domain 
and a membrane proximal stalk. Paramyxoviruses with HN attachment proteins 
bind to sialic acid and possess a neuraminidase function (4). The morbilliviruses 
within the Paramyxoviridae family use the attachment protein H, which binds sialic 
acid but does not have neuraminidase activity. Interestingly, the G protein of 
henipaviruses is unable to bind or cleave sialic acid. Instead, it interacts with the 
protein receptor Ephrin B2 or Ephrin B3 to promote close contact between the viral 
and cellular membranes for fusion events (4). Along with mediating initial binding 
events with a cell, paramyxovirus attachment proteins are reported to have fusion- 
promoting functions, since co-expression of both the attachment and fusion protein 
is required for viral spread (4). Some studies have suggested that the attachment 
protein and F protein must physically interact to promote membrane fusion (18). 
However, the mechanisms that regulate this attachment protein-dependent 
triggering are not fully understood. 
Paramyxoviruses express homotrimeric type I F proteins that undergo 
irreversible conformational changes to mediate membrane fusion events between 
the virus and a cell. Domains of the protein include a hydrophobic fusion peptide 
(FP), two heptad repeat regions (HRA and HRB), a single-pass transmembrane 
domain (TMD), and a C-terminal cytoplasmic tail (CT). The F protein is synthesized 
at the endoplasmic reticulum (ER) in an inactive precursor form (F0). During 
translation, the protein inserts into the ER membrane and folds into its trimeric 
structure. Proper folding of the F protein is essential for its triggering function which 
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requires dynamic conformational changes. The newly synthesized F0 must 
undergo proteolytic cleavage to generate the metastable prefusion form (F1+F2) 
that is capable of mediating fusion events once triggered. Proteolytic cleavage of 
F0 yields the disulfide-linked heterodimer F1+F2 which helps to properly position 
the FP and may lower the energy barrier for F protein triggering (FIG 1.2) (4). The 
F protein must also undergo glycosylation. Though all paramyxovirus F proteins 
are glycosylated, the glycosylation sites vary depending on the virus. For HeV F, 
four glycosylation sites were shown to be required for proper folding and fusion. 
Two of these glycosylation sites are present in the F2 subunit (N67 and N69) and 
two are present in the F1 subunit (N414 and N464) (19). 
Proteolytic cleavage of the F protein is an essential step for all 
paramyxoviruses. Without this step, the F protein is maintained in an inactive form 
that prohibits the virus from fusing with target cells to initiate infection. The 
pathways and proteases utilized to process F0 to generate F1+F2 vary amongst the 
paramyxoviruses. Many paramyxovirus F proteins are processed by the protease 
furin as they are transported through the trans-Golgi network to reach the cell 
plasma membrane (20). The furin enzyme belongs to the subtilisin-like proprotein 
convertase family and is enriched in the Golgi apparatus. It recognizes the 
sequence R-X-K/R-R and cleaves proteins to generate their mature or active form. 
This F protein proteolytic cleavage pathway is used by paramyxoviruses such as 
PIV5 and MeV (21, 22). Neither HeV F nor NiV F contains the furin recognition 
sequence. Instead, these henipaviruses have been shown to utilize the cellular 
protease cathepsin L to generate the metastable F1+F2 heterodimer (23-25). 
Cathepsin L is an endosomal/lysosomal protease that is typically recognized for 
its role in destruction of intracellular and endocytosed proteins. Both HeV F and 
NiV F possess endocytosis motifs within their CTs and trafficking signals in their 
TMDs (26-28). After trafficking to the plasma membrane, the CT motifs signal for 
the F proteins to be endocytosed. The F proteins are processed by cathepsin L in 
a pH-dependent manner within recycling endosomes before being trafficked back 
to the cell surface where they can participate in fusion events (FIG 1.3). 
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To mediate fusion, the paramyxovirus F protein must overcome the 
energetically unfavorable process of merging two lipid bilayers. The F protein 
provides the energy required for this process by refolding from its metastable 
conformation into a stable, low energy, postfusion state. After the G protein binds 
to the target cell receptor, interactions between the F and G proteins are thought 
to trigger conformational changes in the F protein for fusion, and different models 
have been suggested for these interactions. The “clamp” model suggests that the 
F and G proteins form a complex that is trafficked to the cell surface, allowing the 
G protein to stabilize the F protein in its metastable state. Upon receptor binding, 
the F protein dissociates from the G protein to undergo refolding events. In the 
“association” model, the G protein is not required to stabilize the F protein 
prefusion state. Rather, the G protein binds to its receptor and then interacts with 
the F protein in a manner that destabilizes the prefusion form to promote fusion 
(18). Once triggered, the hydrophobic FP of the F protein is inserted into a target 
cell membrane. Further conformational changes irreversibly transform the F 
protein into a stable six-helix bundle while simultaneously generating a fusion pore 
through which the viral genome can be released into the target cell (4). 
Work on the fusion proteins of different viruses, including influenza virus 
and human immunodeficiency virus, has shown that the TMD plays a significant 
role in promoting fusion (29-39). Our lab has explored various aspects of the HeV 
F TMD to better understand its role in protein folding, stability, and fusion 
promotion. The TMD region has been studied in isolation using sedimentation 
equilibrium analysis, an ultracentrifugation method for quantitating protein 
molecular masses and protein-protein interactions. Results showed that the HeV 
F TMD associated as a trimer in the absence of the rest of the protein (40). 
Peptides mimicking the HRB region were added to isolated TMDs and were found 
to disrupt TMD-TMD interactions. Though HRB peptides fail to associate in 
isolation, they form a trimeric coiled coil within the HeV F prefusion conformation. 
The HRB coiled coil acts as a stalk that is N-terminally connected to the globular 
head domain and C-terminally connected to the TMDs. Spacing between the HRB 
and TMD was shown to be important for protein stability but changes in the spacing 
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did not impact TMD interactions. Together, these results suggest that TMD 
interactions contribute to the stability of the HRB region (41). 
C-terminal residues of the HeV F TMD were also analyzed to determine 
their role in TMD interactions. Mutation of the C-terminal TMD residues 
dramatically inhibited fusogenic activity, suggesting that the β-branched residues 
in this region promote TMD interactions required for fusion (41). The HeV F TMD 
also includes a heptad repeat leucine-isoleucine zipper, and these residues were 
shown to be important for HeV F prefusion stability. Overall, these findings 
highlight the importance of HeV F TMD interactions for maintaining the metastable 
prefusion conformation and for promoting fusion events. These results generated 
the hypothesis that the HeV F TMDs must dissociate to initiate refolding events. 
This idea is explored in the work described in Chapter 3, in which the HeV F TMDs 






Pneumoviridae is another family classified within the Mononegavirales 
order. This taxon was previously classified as a subfamily within Paramyxoviridae 
but was reclassified in 2016 (42). The pneumovirus genomes, which range from 
13 to 15 kilobases, encode 9 to 11 proteins. Pneumovirus virions vary in size and 
shape, but they are often filamentous and up to 2 µm in length (42). Two 
pneumoviruses that cause disease in humans by infecting epithelial cells of the 
respiratory tract are the respiratory syncytial virus (RSV) and human 
metapneumovirus (HMPV). This family also includes avian metapneumovirus, 
which infects birds, and the murine and bovine orthopneumoviruses, which infect 
mice and cattle, respectively. 
The pneumovirus life cycle begins with the virus fusing its membrane with 
a host cell membrane. Like the paramyxoviruses, this process is mediated by the 
F protein which is maintained in a metastable state until it is triggered to undergo 
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conformational changes that merge the host cell membrane with the viral lipid 
bilayer. In contrast to the paramyxoviruses, studies of RSV and HMPV suggest 
that the attachment protein G is dispensable for initiating infection (4). RSV and 
HMPV particles are first endocytosed, and fusion events occur within the 
endosome (43, 44). For HMPV, low pH has been shown to trigger the F protein for 
some strains (45, 46). Since viruses in the Pneumoviridae family possess a 
negative-sense RNA genome, the viral particle must also deliver proteins involved 
in transcription and replication of the genome, including the large polymerase 
protein (L), P protein, M2-1, M2-2, and the N protein, to the host cell. Like the 
paramyxovirus N protein, the pneumovirus N protein interacts with the RNA 
genome to form the nucleocapsid which protects the genetic material from host 
cell nucleases and acts as a template for transcription and replication (47). The P 
protein interacts with the N protein and recruits the polymerase and M2-1 to the 
viral nucleocapsid to form a replication complex (48). The matrix-2 proteins, M2-1 
and M2-2, promote polymerase processivity and regulate the switch between viral 
replication and transcription, respectively (49, 50). The polymerase initiates 
transcription at the 3’ terminus of the genome and sequentially produces 
transcripts for each gene. The genes are separated by non-transcribed intergenic 
regions, and each gene contains a short gene start and gene end signal. As the 
polymerase moves along, it scans the intergenic regions until it finds the next gene 
start sequence. Since the polymerase sometimes falls off during this process, 
transcripts for the genes closer to the 3’ terminus are produced in greater 
abundance than those at the 5’ terminus. The transcripts are capped and 
polyadenylated prior to translation by the host cell ribosome complex (48). Once 
the virus accumulates a pool of proteins, it switches from transcription to replication 
to produce full-length, positive-sense antigenomes. This switching mechanism is 
not fully understood, but it likely involves the M2-2 protein (51). M2-2 is also 
thought to play a role in virulence by inhibiting the innate immunity of the host (52). 
The polymerase then uses the antigenome as a template to produce negative- 
sense genomes that can be formed into ribonucleoproteins and packaged into new 
viral particles. Viral particle assembly is regulated by the matrix protein (M), which 
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mediates interactions between the host cell membrane and the ribonucleoprotein 
complex (53). Self-assembly of the viral proteins at the plasma membrane is 
followed by budding events in which the virus acquires a lipid bilayer. 
Human metapneumovirus 
 
HMPV is a member of the Pneumoviridae family that causes acute 
respiratory infections. Though HMPV was discovered in the Netherlands in 2001, 
research suggests that the virus circulated since at least the 1950s before it was 
identified. HMPV was likely not identified earlier due to similarities with the 
symptoms of RSV infections and due to difficulties associated with propagating the 
virus in cell culture. Respiratory illness linked to HMPV infection can be particularly 
dangerous for infants, children, immunocompromised individuals, and the elderly 
(49). HMPV consists of two genetic groups known as A and B, which are divided 
into the four subgroups A1, A2, B1, and B2 (54). The seasonal pattern for HMPV 
infections is similar to other respiratory pathogens, such as RSV and influenza, but 
HMPV tends to peak in later months (49). Hospitalization rates for children with 
HMPV infections are highest until they reach age one, but reinfections often occur 
throughout childhood (49). Nearly all people experience an HMPV infection by the 
age of five. However, immunity against the virus is typically weak, so HMPV 
infections reoccur in adulthood (55). Symptoms of HMPV infection are similar to 
other respiratory viruses and include sore throat, cough, fever, nasal congestion, 
and shortness of breath (49). Bronchiolitis and pneumonia are often diagnosed in 
conjunction with HMPV infection (49). Currently, there are no approved vaccines 
or antivirals to combat HMPV infections. 
The HMPV genome is approximately 13,000 nucleotides and includes eight 
genes in the following order: 3’-N-P-M-F-M2-SH-G-L-5’. These eight genes 
encode nine proteins, since the matrix-2 gene sequence codes for two proteins, 
M2-1 and M2-2. With the RNA genome, these proteins form the HMPV particle 
which is surrounded by a lipid bilayer derived from the host (FIG 1.4). Unlike RSV, 
the HMPV genome does not include the non-structural proteins NS1 and NS2 
which are thought to play a role in inhibiting the antiviral response. The F protein, 
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G protein, and SH protein are found within the viral membrane. The M protein lines 
the inner layer of the viral membrane and plays a role in assembly and budding. 
The membrane surrounds the helical nucleocapsid, which interacts with the P 
protein, polymerase, M2-1, and M2-2 (52). Delivery of the nucleocapsid into a 
target cell leads to the formation of viral factories, called inclusion bodies (IBs), in 
the cytoplasm to enhance replication and transcription (FIG 1.5) (56). These 
structures are particularly interesting because they represent a potential target for 
the development of antivirals to treat HMPV infections. 
The role of inclusion bodies in pneumovirus infections 
 
The pneumoviruses HMPV and RSV, along with other specific members of 
the Mononegavirales order, form spherical structures known as IBs in the 
cytoplasm of infected cells (57-65). Though IBs were once thought to serve as 
sites of accumulation for misfolded proteins, they have more recently been shown 
to serve as sites of viral replication and transcription for viruses such as HMPV, 
RSV, MeV, rabies virus (RABV), and Ebola virus (56, 57, 66-73). These findings 
suggest that IB formation is a common mechanism utilized by negative-strand RNA 
viruses to promote replication. Viral replication components, including the P 
protein, N protein, L protein, and viral RNA, concentrate within IBs to produce viral 
transcripts, antigenome, and genome (56, 67). Microscopic analysis of 
pneumovirus IB structures has shown that they form in the absence of membranes 
and often localize near the nucleus (56, 74). The minimum components required 
to reconstitute pneumovirus IB-like structures in cells are the P protein and N 
protein (65, 75). 
For HMPV, IBs containing viral genomic and antigenomic RNA are easily 
detected by 24 hours post infection and were shown to form when smaller 
replicative spots coalesce into larger inclusions (56). As the infection progresses 
to later time points, IBs are maintained at low numbers within the cell (56). This is 
due in part to the fusion of IBs in a cytoskeleton-dependent manner. Though 
microtubule polymerization does not appear to be required for IB coalescence, 
actin polymerization is critical for forming these structures to promote efficient viral 
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replication and transcription (56). The compartments are highly dynamic and 
undergo fusion and fission. The dynamics are similar to the nature of cellular 
structures such as processing bodies (P-bodies) and stress granules, but HMPV 
IBs represent a distinct structure within the cytoplasm to enhance the viral life cycle 
(56). Additional studies have shown that HMPV primarily spreads through a direct 
cell-to-cell mechanism, in which infected cells form long, branched extensions that 
connect to uninfected cells (76). Viral RNA and structures resembling IBs were 
identified within extensions, suggesting that the dynamic nature of IBs may be 
important for spreading infectious materials to new target cells (76, 77). 
RSV inclusions were first described in 1970 using electron microscopy 
techniques to study infected cells. The RSV IBs were dense and contained 
filamentous structures (64). More recent studies have shown that RSV IBs serve 
as a major site for viral RNA synthesis. Similar to HMPV, RSV IBs are not detected 
at early time points of infection, suggesting that these structures form as viral 
components accumulate in the cytoplasm and as smaller structures coalesce (67). 
Additionally, RSV IBs were shown to possess sub-compartments, called IB- 
associated granules (IBAGs), which concentrate nascent viral mRNA and the M2- 
1 protein (67). Interestingly, viral genomic RNA, N protein, P protein, and L protein 
were excluded from IBAGs within the IBs (67). These findings suggest that IBAGs 
function in sorting viral mRNA with the help of the M2-1 protein, which competes 
with the P protein to bind RNA (67). This is the first description of an additional role 
for IBs to serve as viral mRNA sorting sites. RSV IBs have also been implicated in 
sequestering the NF-κB subunit p65, suggesting that IBs help to antagonize the 
innate immune system response from the host (78). Like HMPV, RSV has been 
shown to induce the formation of intercellular extensions which may serve as a 
route for transporting viral IB components directly from cell-to-cell (79). 
Liquid-liquid phase separation and inclusion body formation 
 
The dynamic nature of viral IBs and the similarities they share with other 
membrane-less cell structures led to the hypothesis that IBs are liquid organelles 
formed via liquid-liquid phase separation (LLPS) within the cytoplasm (FIG 1.6A). 
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The biological cell is highly organized to bring specific components together to 
increase reaction kinetics. Membranes surrounding classic organelles, such as the 
ER and Golgi, provide a physical barrier to concentrate materials for a particular 
set of biochemical reactions (80). In addition to membrane-bound compartments, 
IBs and other membrane-less compartments concentrate proteins and nucleic 
acids in the absence of a physical barrier. Examples include nucleoli, Cajal bodies, 
P-bodies, and stress granules which house different varieties of reactions. LLPS, 
which is thought to drive the formation of many of these structures, allows for the 
concentration of materials to form condensed liquid droplets (81). The nucleolus, 
which was first described in the 1830s, was the first membrane-less compartment 
to be observed by microscopy (80, 82). Improvements in microscopes led to the 
discovery of many other membrane-less compartments within the nucleus, the 
cytoplasm, and at the plasma membrane (80). However, scientists have struggled 
to explain the properties that allow for the formation and maintenance of these 
structures. Analysis of P granules in Caenorhabditis elegans germ cells led to the 
first suggestion that these structures were liquid-like in nature (80). Though the 
membrane-less compartments found in cells have diverse functions and 
characteristics, scientists have now classified them together as biomolecular 
condensates since they generally form through the same process of phase 
separation (80). 
The condensation reaction relies on the formation of weak, multivalent 
protein-protein and protein-nucleic acid interactions. This process is influenced by 
factors such as pH, protein concentration, charge, RNA-binding, and post- 
translational modifications (83). Additionally, protein features such as low 
sequence diversity, low-complexity regions, and blocks of oppositely charged 
residues often contribute to biomolecular condensate formation (84). Although 
LLPS has been implicated in liquid organelle formation for normal cellular 
functions, it also plays a role in neurodegenerative disease. In some diseases, 
such as amyotrophic lateral sclerosis and Alzheimer’s, mutated proteins in liquid 
droplets cause the condensates to undergo a liquid-to-solid transition or to 
nucleate aggregation, leading to pathological effects (83). Recent studies of some 
14  
RNA viruses have highlighted LLPS as the mechanism utilized within the 
cytoplasm of a host cell to promote processes such as viral replication, 
transcription, and assembly. Specifically, several negative-sense, single-stranded 
RNA viruses have been shown to form cytoplasmic IBs via LLPS which contain 
viral RNA and proteins (64, 83-86) (66, 85-88). 
Characterization of proteins that phase separate under physiological 
conditions has revealed specific features that are common to these molecules. 
Condensates often consist of scaffold proteins, which drive phase separation, and 
client proteins, which partition into liquid droplets (83). One protein feature that 
promotes multivalent interactions between scaffold proteins, client proteins, and 
nucleic acids is intrinsically disordered regions (IDRs), which are dynamic in 
solution. IDRs often give proteins the ability to interact with a variety of partners 
and are associated with high rates of evolution (89). In addition, proteins with IDRs 
are frequently found in condensates that contain RNA (80). HMPV and other 
viruses within the Mononegavirales order possess a P protein that acts as a 
cofactor for the RNA-dependent RNA polymerase by stabilizing interactions with 
the RNA template during replication and transcription. The P proteins of paramyxo- 
, pneumo-, and rhabdoviruses have been shown to include long IDRs (84, 90, 91). 
Paramyxovirus and pneumovirus P proteins associate as homotetramers via a 
central oligomerization domain that is flanked on both sides by large IDRs. In 
contrast, the rhabdovirus P protein contains a central dimerization domain that is 
flanked by IDRs (90). The oligomeric and intrinsically disordered nature of these P 
proteins allows them to interact with multiple binding partners to form the viral 
replication complex. 
Negative-sense, single-stranded RNA viruses also possess N proteins with 
features that may promote phase separation in cells. First, a cleft of positively 
charged amino acids gives the N protein the ability to strongly bind RNA. In addition 
to coating the RNA genome to form stable nucleocapsids, a pool of N protein is 
maintained in a monomeric state (N0) so that it can be sequestered to the viral 
replication complex to bind newly synthesized RNA. Like viral P proteins, some 
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viral N proteins contain IDRs. However, the IDRs found in negative-strand virus N 
proteins are typically smaller than the IDRs in P proteins. For instance, in the 
paramyxovirus MeV, 30 percent of the N protein is disordered, compared to 75 
percent of the P protein (91). Together, these viral protein characteristics suggest 
that the P protein and N protein are predisposed to participate in LLPS for the 
formation of inclusions to enhance viral replication. 
HMPV phosphoprotein and nucleoprotein 
 
Since the HMPV P and N proteins represent the minimum requirements for 
IB-like structure formation, further analysis of these proteins is needed to 
understand how they may regulate LLPS for IB formation during infection. The 
HMPV P protein plays various roles during the viral life cycle, particularly during 
replication and transcription. It is 294 amino acids in length and contains a stable, 
tetrameric coiled coil domain from residue 158 to 237. The hydrophobic amino 
acids that line the interior of the coiled coil are highly conserved within the 
Pneumoviridae family (84). Overall, the protein sequence includes approximately 
35 percent lysine, arginine, glutamic acid, and aspartic acid residues which are 
often present in repetitive blocks (84). The tetramerization domain is surrounded 
by IDRs at the N- and C-termini (FIG 1.7). Specifically, the N-terminus includes 
four long IDRS, and the C-terminus includes four relatively shorter IDRs (47). 
HMPV P binds to the polymerase primarily through its central oligomerization 
domain and some regions in the C-terminus (92). The disordered regions of the N- 
and C-termini are available to interact with other proteins to tether them to the 
polymerase for replication and transcription activities (92). The disordered HMPV 
P N-terminus interacts with RNA-free N (N0). This chaperoning role for the P 
protein is common among negative-strand viruses and is crucial so that N does 
not oligomerize or bind host nucleic acids (47, 93-96). The interaction is mediated 
by a molecular recognition element at the beginning of the N-terminal region of the 
P protein (82). This region of P binds to a hydrophobic groove within the C-terminal 
domain of HMPV N to block oligomerization (47, 92). 
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The C-terminus of HMPV P also plays a role as an adaptor for the N protein 
by binding to N-RNA to facilitate interactions with the polymerase (47). This portion 
of P is proposed to help remove the template RNA from the ribonucleoprotein 
complex to feed it into the polymerase tunnel (47, 92). Interestingly, recent cryo- 
electron microscopy findings for the HMPV P protein-polymerase complex suggest 
that the C-terminal regions of HMPV P occupy non-equivalent positions within the 
structure (92). Upon binding to the polymerase, portions of the HMPV P C-terminus 
undergo disorder-to-order transitions. This led to the development of a model in 
which three HMPV P C-terminal domains displace genomic RNA from the 
ribonucleoprotein, while the other P C-terminal domain plays a structural role at 
the polymerase tunnel (92). In addition to binding the N0, N-RNA, and the 
polymerase, HMPV P is proposed to bind the processivity factor M2-1 via residues 
136-161 based on studies of RSV (97-99). Together, these findings highlight the 
dynamic nature of the P protein as an adaptor for recruiting viral proteins to the 
polymerase. 
The HMPV N protein, which consists of 394 amino acids, encapsidates the 
viral genome and protects it from host cell nucleases. The protein consists of two 
globular domains, the N-terminal domain (NTD) and C-terminal domain (CTD), 
which play a role in binding RNA within the positively charged groove located 
between the domains. In addition, the domains are attached to NTD and CTD arms 
that help the N protomers oligomerize. The N protein is found in two conformations, 
depending on whether it is bound to P protein or RNA. HMPV N and other negative- 
strand virus N proteins are known for their ability to readily bind nucleic acid and 
oligomerize into complex structures. Therefore, wild type (WT) HMPV N protein is 
generally purified in the form of decameric RNA-bound rings. In the crystallized N 
protein ring structure, the RNA is tightly bound between the NTD and CTD within 
a positively charged cleft of each N protomer (47). Each N protein interacts with 
seven RNA nucleotides. This is unique compared to the closely related 
paramyxoviruses which show six nucleotides bound to each N protomer within a 
ring structure (47). To form the oligomerized ring, the NTD arm and CTD arm of 
each N protein latches to the subsequent N protomer (47). When N0 protein is 
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recruited to newly synthesized viral RNA, the P protein is displaced, and the N 
protein CTD arm is proposed to flip upward to accommodate the insertion of the 
viral RNA into the positively charged cleft (47). Understanding the complex 
interactions between HMPV N, P, and viral RNA is crucial for analyzing LLPS 
experiments in vitro and in cells. 
Methods for analyzing LLPS 
 
Investigations of biomolecular condensates led to the development of 
criteria to define the properties of liquid organelles in cells: 
 
1. Liquid organelles undergo fusion and fission (FIG 1.6B). 
 
2. The internal contents of liquid organelles diffuse rapidly. 
 
3. Liquid organelles possess a round shape due to surface tension. 
 
Virologists have used these criteria to study the formation and nature of IBs 
in cells. Tools including live cell imaging and fluorescence recovery after 
photobleaching (FRAP) have been important for generating qualitative and 
quantitative data regarding the dynamics of IBs. For FRAP, fluorescently-tagged 
viral proteins have been utilized to assess the diffusion of components within IB 
structures (FIG 1.8). FRAP analysis of MeV, RABV, VSV, and RSV IBs has shown 
that the contents of these structures possess diffusion rates that are similar to other 
known liquid organelles (64, 83, 84, 86) (66, 85, 86, 88). Live cell imaging has 
allowed for observation of the spherical shape of viral IBs over time, which is 
deformed during fusion and fission events and subsequently recovered. 
 
In addition to cellular studies of IBs, purified protein systems are a powerful 
tool for understanding the basic LLPS mechanisms of viral proteins in vitro. The 
advantage of conducting experiments with purified proteins is that the simplistic 
system allows for the identification of specific components that are required for 
phase separation (83). LLPS of purified systems is generally analyzed using light 
microscopy, fluorescence microscopy, and turbidity assays. Phase separation of 
18  
the purified protein may be induced by modifying a factor such as ionic strength, 
pH, temperature, or by adding RNA or another protein binding partner. The protein 
solution can then be plated and imaged with microscope to look for the presence 
of liquid droplets. 
 
Turbidity assays are used in conjunction with microscopy analysis to detect 
changes in absorbance as protein droplets form in solution. The assemblies scatter 
visible light as they form, which can be analyzed using optical density 
measurements, generally between wavelengths of 340 and 400 nm (83). 
However, turbidity measurements lack some sensitivity because they cannot 
differentiate the size or shape of assemblies in solution (83). For instance, a protein 
prone to aggregation may give high absorbance readings, even though it does not 
form liquid droplets. Thus, turbidity measurements must be considered along with 
microscopy results to more clearly determine if a protein phase separates. 
Centrifugation is also a useful tool for analyzing proteins that undergo LLPS in 
vitro. First, LLPS of a solution is induced by changing specific conditions. Then, 
the dense phase that forms is sedimented by centrifugation. The concentration of 
the light phase can then be measured spectroscopically (83). 
 
Other in vitro methods provide crucial data for understanding the material 
properties of liquid droplets. Though FRAP has been important for analyzing IBs 
in cells, it can also be utilized to quantify the mobility of molecules within phase 
separated droplets in vitro. This technique has been particularly useful for 
understanding the effects of RNA on protein solutions (83). Additionally, fusion of 
liquid droplets can be quantitatively analyzed to determine the inverse capillary 
viscosity. The inverse capillary viscosity is the ratio of viscosity to surface tension. 
With other calculations, this analysis provides data regarding the chemical nature 
of the surface of liquid droplets (83). In combination, cellular and in vitro phase 
separation experiments provide insight into the mechanisms regulating viral IB 
formation for negative-strand viruses. Future efforts to analyze LLPS and viral 
replication must focus on bridging the gap between cellular and in vitro work. 
Together, these studies will open new doors to understanding how negative-strand 
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Cell entry and replication are critical aspects of the basic viral life cycle that 
must be understood to effectively combat pathogens which cause human disease. 
We are particularly interested in understanding how these processes occur for 
negative-strand RNA viruses, which are notable for their high mutation rates. High 
mutation rates contribute to viral evolution, which means that these viruses are 
excellent at finding new ways to evade the host immune system. Additionally, 
these mutations can lead to the emergence of novel infections within humans. 
Thus, work on these viruses is important for determining how we can protect 
populations against current and future threats. We study the basic mechanisms of 
cell entry and replication by analyzing the proteins of HeV and HMPV. Our work 
has identified similarities and differences among negative-strand viruses which 
may be crucial for learning how we can target these deadly pathogens. 
For enveloped viruses, studies of cell entry focus on explaining the 
mechanisms that allow for the fusion of two membranes, an energetically 
unfavorable process. Years of research on class I fusion proteins have generated 
a model for membrane fusion. However, gaps still exist in the model and warrant 
further research. The high kinetic barrier associated with membrane merger is 
overcome by the fusion protein which sits within the viral membrane. Many copies 
of the fusion protein stud the surface of the virus, ready to be triggered to mediate 
fusion with a cell. The fusion protein must be held in a metastable prefusion state, 
a higher energy conformation, until it is triggered to undergo the irreversible 
refolding events which lead to the formation of the lower energy postfusion 
conformation. Our interest in viral fusion has focused on the interactions within the 
HeV F protein that maintain the stability of the prefusion conformation. In addition, 
we have explored changes in these interactions which occur upon triggering. Our 
work highlights the importance of the HeV F TMD, which is required for anchoring 
the protein and plays a role in proper folding, stability, trafficking, and fusogenic 
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activity. Studies of the basic mechanisms of HeV F are needed to build a complete 
picture of viral membrane fusion. Novel information that is discovered about 
paramyxovirus F proteins may also be beneficial for the development of new 
vaccines and therapeutics. In Chapter 3, we explore the hypothesis that HeV F 
TMD dissociation is required for subsequent conformational changes that drive 
fusion. We tested this idea by locking the TMDs together with disulfide bonds to 
see how HeV F stability and fusion would be impacted. Our results provide support 
for this hypothesis and show for the first time that blocking HeV F TMD dissociation 
abolishes fusogenic activity. 
Once cell entry is accomplished, the virus must take on the next challenge 
of replicating its genetic material and producing proteins which will be packaged 
into new virions. Many negative-strand RNA viruses have evolved mechanisms to 
house replication and transcription within distinct cytoplasmic compartments, 
which we call IBs. The lack of a physical barrier around these structures creates 
challenges for analyzing and targeting the compartments. A combination of cellular 
and in vitro studies is important for describing the interactions that allow these 
dynamic structures to form. Cellular experiments have provided useful findings 
regarding the nature of viral IBs during different stages of infection. Since proteins 
and other materials can freely diffuse into IBs in cells, in vitro analysis of purified 
viral proteins provides an opportunity to study IB components in isolation. IB 
formation is a hallmark of HMPV and RSV infections. Until now, HMPV IBs have 
not been characterized as liquid organelles formed by LLPS. In Chapter 4, we 
analyze the basic components of HMPV IBs, the N and P proteins, in our in vitro 
system to explain the basic interactions that promote IB formation. The HMPV N 
and P proteins phase separate to form liquid droplets in vitro, supporting that LLPS 
is the mechanism which leads to HMPV IB formation. Additionally, we show that 
HMPV P acts as a scaffold protein to recruit oligomeric or monomeric N protein to 




Figure 1.1 HeV life cycle. A HeV virion attaches to a target cell via an interaction 
between the G protein and the receptor Ephrin B2/B3. The F protein undergoes 
conformational changes to merge the viral membrane with the target cell 
membrane. The viral genome is released into the cytoplasm where it undergoes 
replication and transcription. Replication of the genome yields antigenome which 
is then used to generate new negative-sense RNA genome copies. Transcription 
of the genome produces viral mRNAs which are translated into viral proteins k and 
assembled at the cell surface into new virions. Nascent virions bud from the 







Figure 1.2. Cleavage of HeV F0 to generate F1+F2. The HeV F protein includes 
a hydrophobic fusion peptide (FP, pink), heptad repeat A (HRA, yellow), heptad 
repeat B (HRB, teal), transmembrane domain (TMD, purple), and C-terminal 
cytoplasmic tail (CT, blue). After trafficking to the cell surface, the inactive form of 
HeV F (F0) is endocytosed and proteolytically cleaved by cathepsin L into a 
disulfide-linked heterodimer (F1+F2). Then, HeV F is transported back to the cell 




Figure 1.3. HeV F processing in the host cell. The precursor F0 (red) is trafficked 
through the secretory pathway to reach the plasma membrane. F0 is then 
endocytosed and cleaved by cathepsin L within the endosome to generate F1+F2 




Figure 1.4. HMPV particle schematic. The HMPV virion contains a negative- 
sense, single-stranded RNA genome that is coated with N protein. The genome is 
enclosed within a lipid bilayer derived from the host cell. The M protein lines the 
inside of the viral membrane. The SH, F, and G proteins are transmembrane 
proteins within the bilayer. The F protein undergoes conformational changes to 
fuse the viral membrane with a target cell membrane. The coated genome can 
then be released with its associated proteins into the cytoplasm of the cell where 




Figure 1.5. HMPV life cycle. An HMPV virion attaches to a target cell, leading to 
endocytosis of the particle. The viral particle fuses its membrane with the 
endosomal membrane to release the genome and its associated proteins. The 
genome is replicated and transcribed in the cell cytoplasm. As the infection 
progresses, membrane-less IBs form to house replication and transcription events. 
The mRNAs for viral membrane proteins (F, G, SH) are translated at the ER and 
trafficked to the cell surface. Viral proteins involved in replication and transcription 
are translated in the cytoplasm and then localized to IBs. New viral particles are 
assembled at the plasma membrane where they can bud from the surface. The 
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Figure 1.6. LLPS diagrams. (A) Molecules condense from a single phase to form 
a droplet phase. (B) Phase separated liquid droplets are dynamic structures which 





Figure 1.7. HMPV P schematic. HMPV P protomers associate via a central 
oligomerization domain to form a tetramer. The oligomerization domain is flanked 









Figure 1.8. FRAP diagram. FRAP analysis of live cells requires the use of 
fluorescent labels which can be bleached by a laser. After a specific area of 
fluorescence is bleached, the fluorescence intensity is monitored over time. This 
data can be used to compare fluorescence recovery rates for different structures 
within the cell. 
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Chapter 2: Materials and Methods 
 
 
HeV fusion project 
Plasmids 
 
Plasmids containing HeV F and G were kindly provided by Dr. Lin-Fa Wang 
from the Australian Animal Health Laboratory. The HeV F TMD mutants were 
generated in pGEM using the QuikChange Site-Directed Mutagenesis Kit from 
Stratagene and subcloned into pCAGGS using the forward primer 5’ GCG ATT 
GAA TTC TAA GCA ATG GCT ACA CAA GAG 3’ and reverse primer 5’ CG GCG 
GCC ATG CAT ATT TTA TGT TCC AAT ATA ATA 3’ for PCR amplification. The 
constructs were verified by sequencing. 
Antibodies 
 
Anti-peptide antibody to the HeV F cytoplasmic tail residues 527-539 (25) 
were used to pull down WT HeV F or the TMD mutant constructs. The prefusion 
conformation-specific antibody, mAb 5B3, generously provided by Dr. Christopher 
Broder (Uniformed Services University of the Health Sciences) was also used to 
detect HeV F (100). 
Cell lines 
 
Vero cells (ATCC) and BSR cells (provided by Karl-Klaus Conzelman, 
Pettenkofer Institut) were maintained in Dulbecco’s modified Eagle’s media 
(DMEM; Invitrogen) supplemented with 10% fetal bovine serum (Sigma). For the 
BSR cells, 0.5 mg/mL geneticin (Gibco) was added to the media with every third 
passage to select for T7 polymerase-expressing cells. 
Syncytia assay 
 
Vero cells in 6-well plates were transiently transfected using Lipofectamine 
3000 (Invitrogen) per the manufacturer’s protocol with pCAGGS-HeV F and 
pCAGGS-HeV G at a 1:3 ratio. At 48 hr post-transfection, the cells were imaged 




Vero cells in 6-well plates were transiently transfected using Lipofectamine 
and Plus (Invitrogen) per the manufacturer’s protocol with pCAGGS-HeV F or one 
of the TMD mutants. At 24 hr post-transfection, the cells were washed 2X with PBS 
and starved with DMEM lacking cysteine and methionine (Cys-/Met-) for 45 min. 
Then, the cells were labeled for 3 hr with Cys-/Met- DMEM containing Tran35S- 
label (100 µCi/mL; MP Biomedicals). The cells were washed 3X with PBS and 
lysed with 500 µL RIPA lysis buffer (100 mM TrisHCl (pH=7.4), 150 mM NaCl, 
0.1% SDS, 1% Triton X-100, 1% deoxycholic acid, 1 mM phenylmethylsulfonyl 
fluoride (Sigma), 25 mM iodoacetamide (Sigma), 1:100 aprotinin (Calbiochem)). 
The sample lysate was centrifuged at 136,500 x g for 15 min at 4 ºC, and the 
supernatant was incubated for 3 hr with 4 µL anti-peptide antibody. Then, the 
sample was incubated with 30 µL protein A-sepharose beads (ThermoFisher) for 
30 min at 4 ºC with rocking and washed 2X with RIPA buffer + 0.30 M NaCl, 2X 
with RIPA buffer + 0.15 M NaCl, and 2X with SDS wash II (150 mM NaCl, 50 mM 
Tris-HCl (pH=7.4), 2.5 mM EDTA). Depending on the experiment, the samples 
were resuspended with loading buffer lacking or containing dithiothreitol (DTT; 
Goldbio) for non-reducing or reducing conditions, respectively. Then, the samples 
were boiled and separated using 3.5% polyacrylamide gels for SDS-PAGE and 
visualized using the Typhoon imaging system (GE Healthcare). For the tris(2- 
carboxyethyl) (TCEP) (Calbiochem) treatment experiments, 1 mL of 6 mM TCEP 
in DMEM supplemented with 10% FBS was added to the cells following the 
metabolic label. The cells were incubated with the TCEP solution for 3 hr at 37 ºC 
before washing 2X with PBS and adding RIPA lysis buffer. Results were visualized 
using the Typhoon imaging system. 
Reporter gene assay 
 
Vero cells in 6-well plates were transiently transfected using Lipofectamine 
and Plus per the manufacturer’s protocol with 0.8 µg luciferase under the control 
of the T7 promoter, 0.9 µg pCAGGS-HeV G, and 0.3 µg pCAGGS-HeV F or one 
of the TMD mutants. At 24 hr post-transfection, the Vero cells were washed 1X 
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with PBS and overlaid with BSR cells, previously lifted with trypsin (Invitrogen) and 
diluted in DMEM supplemented with 10% FBS, that stably express the T7 
polymerase for 3 hr at 37 ºC. For specific experiments, 6 mM TCEP was added to 
the overlay media for the 3 hr incubation. Then, the cells were lysed with reporter 
lysis buffer (Promega) and analyzed for luciferase activity using the luciferase 
assay system (Promega) per the manufacturer’s instructions. The Lmax 
luminometer (Molecular Devices; Sunnyvale, CA) was used with a 2 sec delay and 
a 5 sec integration time. Results were normalized to samples expressing WT HeV 
F and G. 
Cell surface biotinylation 
 
Vero cells in 60-mm dishes were transiently transfected using 
Lipofectamine and Plus reagent or Lipofectamine 3000 per the manufacturer’s 
protocol with 4 µg pCAGGS-HeV F or one of the TMD mutants. At 24 hr post- 
transfection, the cells were washed 2X with PBS and starved with Cys-/Met- 
DMEM for 45 min. Then, the cells were radiolabeled for 4 hr in Cys-/Met- DMEM 
containing Tran35S-label. The cells were washed 2X with ice cold PBS (pH=8.0) 
and incubated with 1 mL of 1 mg/mL EZ-Link Sulfo-NHS-Biotin (Pierce) in PBS 
(pH=8.0) for 35 min at 4 ºC with rocking followed by 15 min at room temperature. 
Next, the cells were washed 3X with ice cold PBS (pH=8.0) and 500 µL RIPA lysis 
buffer was added. The sample lysate was centrifuged at 136,500 x g for 15 min at 
4 ºC. The supernatant was transferred to 1.5 mL tubes and incubated with 8 µL of 
the anti-peptide HeV F antibody for 3 hr at 4 ºC with rocking. Next, each sample 
was incubated with 30 µL protein A-sepharose beads for 30 min at 4 ºC with 
rocking. The samples were washed 2X with RIPA buffer + 0.30 M NaCl, 2X with 
RIPA buffer + 0.15 M NaCl, and 2X with SDS wash II. Following the washes, 60 
µL of 10% SDS was added, and the samples were boiled for 10 min, transferred 
to a new tube, and repeated with 40 µL of 10% SDS to give a total of 100 µL. Ten 
µL of each sample was separated and resuspended in 2X SDS loading buffer 
containing DTT for total protein expression analysis. The remaining 90 µL of 
sample was treated with 400 µL biotinylation dilution buffer (20 mM Tris (pH=8.0), 
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150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.2% bovine serum albumin (US 
Biological Life Sciences)) and 30 µL streptavidin beads for 1 hr at 4 ºC with rocking. 
The washes described previously were repeated, and the samples were 
resuspended in 2X SDS loading buffer containing DTT. After boiling the samples, 
analysis of HeV F was conducted using 15% SDS-PAGE and visualized using the 
Typhoon imaging system. Quantifications from band densitometry using 
ImageQuant 5.2 were reported as relative expression (%), the sum of F0 and F1, 
normalized to WT HeV F. 
Time course immunoprecipitation 
 
Vero cells in 6-well plates were transiently transfected using Lipofectamine 
and Plus per the manufacturer’s protocol with pCAGGS-HeV F or one of the TMD 
mutants. At 24 hr post-transfection, the cells were washed 2X with PBS, starved 
for 45 min, and metabolically labeled for 3 hr (described previously). Then, the cells 
were washed 3X with PBS and chased with DMEM + 10% FBS. At different time 
points, the cells were washed 2X with PBS and lysed with RIPA lysis buffer. 
Immunoprecipitation was conducted as described for oligomeric analysis, and 
samples were resuspended in 2X SDS loading buffer containing DTT. Samples 
were boiled and analyzed by 10% SDS-PAGE, and band densitometry 
quantifications were performed as described for surface biotinylation. 
Immunoprecipitation with prefusion conformation-specific antibody 
 
To analyze mAb 5B3 binding prior to cell disruption, Vero cells in 60-mm 
dishes were transiently transfected using Lipofectamine and Plus per the 
manufarcturer’s protocol with pCAGGS-HeV F or one of the TMD mutants. At 24 
hr post-transfection, the cells were washed 2X with PBS, starved for 45 min, and 
metabolically labeled in 2 mL overnight label media (85% Cys-/Met- DMEM, 10% 
DMEM + 10% FBS, 5% FBS) containing Tran35S-label for 24 hr. Then, the cells 
were washed 3X with PBS and treated with mAb 5B3 at 1 ug/mL in 1X PBS + 1% 
bovine serum albumin for 1 hr at 4 ºC with rocking. Following the antibody 
incubation, the cells were lysed with RIPA lysis buffer and centrifuged at 136,500 
x g for 15 min at 4 ºC. Control samples were treated with 8 µL anti-peptide antibody 
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for 1.5 hr after being lysed with RIPA lysis buffer and centrifuged. All samples were 
treated with 30 uL protein A-sepharose beads for 1 hr. Then, the samples were 
washed as described previously. After boiling the samples, they were separated 
by 10% SDS-PAGE, and band densitometry quantifications were performed as 
described for surface biotinylation. 
To analyze mAb 5B3 binding following cell disruption, Vero cells in 6-well 
plates were transiently transfected using Lipofectamine and Plus per the 
manufacturer’s protocol with pCAGGS-HeV F or one of the TMD mutants. At 24 hr 
post-transfection, the cells were starved, labeled, lysed, and centrifuged as 
described for oligomeric analysis. Then, the cells were treated with 1 µg/mL mAb 
5B3 or 4 µL anti-peptide Ab for 3 hr. The rest of the immunoprecipitation was 
performed as described for oligomeric analysis. Then, the samples were boiled 
and separated using 10% SDS-PAGE, and band densitometry quantifications 
were performed as described for surface biotinylation. 
 
 
HMPV phase separation project 
Expression and purification of HMPV N0-P 
The CAN97-83 HMPV N0-P construct with a 6X C-terminal His6-tag was 
purchased from GenScript in the pET-29b(+) plasmid. It was cloned into the 
plasmid between the NdeI and KpnI cleavage sites. The construct was expressed 
in E. coli Rosetta 2(DE3) competent cells (Novagen) overnight at 18 °C in terrific 
broth containing kanamycin after induction at an optical density of 0.8 with 1 mM 
isopropyl-β-d-thiogalactopyranoside. Cells were lysed with 20 mM Tris, 500 mM 
NaCl, 10 mM imidazole, pH 7 containing cOmplete EDTA-free protease inhibitor 
cocktail (Sigma), 125 ug/mL lysozyme, and 250 units of Benzonase (Sigma). After 
incubating on ice for 20 min, the solution was sonicated three times at 60% 
intensity for 15 sec. The lysate was spun at 18,000 rpm for 45 min at 4 °C. The 
crude lysate rocked with HIS-select nickel affinity gel resin (Sigma) for 45 min at 4 
°C. The resin was washed one time with lysis buffer and two times with 20 mM 
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Tris, 500 mM NaCl, pH 7. The protein was eluted with 20 mM Tris, 500 mM NaCl, 
300 mM imidazole, pH 7. The eluate was concentrated and buffer exchanged into 
25 mM HEPES, 150 mM KCl, pH 7.5 using a PD-10 desalting column with 
Sephadex G-25 resin (GE Healthcare). Alternatively, some N0-P protein 
preparations were loaded onto a HiTrap Heparin HP column (Sigma) for further 
purification using an increasing NaCl gradient from 200 mM to 1M to remove 
nucleic acid from the sample prior to buffer exchange with the PD-10 column. After 
buffer exchange, the protein was concentrated, flash frozen, and stored at -80 °C. 
Expression and purification of HMPV N-RNA 
 
The CAN97-83 HMPV N construct with a 6X C-terminal His6-tag was 
purchased from GenScript in the pET-29b(+) plasmid. It was cloned into the 
plasmid between the NdeI and KpnI cleavage sites. The construct was expressed 
in E. coli Rosetta 2(DE3) competent cells overnight at 18 °C in terrific broth 
containing kanamycin after induction at an optical density of 0.8 with 1 mM 
isopropyl-β-d-thiogalactopyranoside. Cells were lysed with 25 mM Tris, 1 M NaCl, 
pH 8 containing cOmplete EDTA-free protease inhibitor cocktail, 125 ug/mL 
lysozyme, and 250 units of Benzonase. After incubating on ice for 20 min, the 
solution was sonicated three times at 60% intensity for 15 sec. The lysate was 
spun at 18,000 rpm for 1 hr at 4 °C. The crude lysate was loaded onto a column 
containing pre-equilibrated HIS-select nickel affinity gel resin at 4°C. The resin was 
washed two times with lysis buffer. The protein was eluted with 25 mM Tris, 1 M 
NaCl, 400 mM imidazole, pH 8. The eluate was concentrated and the NaCl 
concentration of the sample was adjusted to 100 mM using 25 mM Tris, pH 8. 
Then, the sample was loaded onto a HiTrap Heparin HP column using an 
increasing NaCl gradient from 200 mM to 1M. Fractions containing the HMPV N 
protein were concentrated and buffer exchanged into 25 mM HEPES, 150 mM KCl, 
pH 7.5 using a PD-10 desalting column with Sephadex G-25 resin. The protein 
was then concentrated, flash frozen, and stored at -80 °C. 
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Expression and purification of HMPV P 
 
The CAN97-83 HMPV P construct was cloned into the plasmid pET 302/NT- 
His between the cleavage sites EcoRI and XhoI. The construct was expressed in 
BL21(DE3) CodonPlus RIL cells (Agilent) overnight at 37 °C in terrific broth 
containing ampicillin after induction at an optical density of 1.4 with 1 mM isopropyl- 
β-d-thiogalactopyranoside. Cells were lysed with 20 mM Tris, 200 mM NaCl, pH 
7.5 containing cOmplete EDTA-free protease inhibitor cocktail and 125 ug/mL 
lysozyme. After incubating on ice for 20 min, the solution was sonicated three times 
at 60% intensity for 15 sec. The lysate was spun at 18,000 rpm for 30 min at 4 °C. 
The crude lysate rocked with HIS-select nickel affinity gel resin (Sigma) for 45 min 
at 4 °C. The resin was washed one time with lysis buffer and two times with 20 mM 
Tris, 200 mM NaCl, 20 mM imidazole, pH 7.5. The protein was eluted with 20 mM 
Tris, 200 mM NaCl, 250 mM imidazole, pH 7.5. The eluate was loaded onto a 
HiTrap Q HP anion exchange chromatography column (Cytiva). The column was 
washed with 20 mM Tris, pH 7.5. Then, fractions were eluted with 20 mM Tris, 1 
M NaCl, pH 7.5. The fractions containing HMPV P were concentrated and buffer 
exchanged into 25 mM HEPES, 150 mM KCl, pH 7.5 using a PD-10 desalting 
column with Sephadex G-25 resin. 
To reduce nucleic acid binding, some HMPV P lysates were treated with 
Benzonase during the cell lysis step. Instead of anion exchange, the HIS-select 
purification was followed by heparin purification using a HiTrap Heparin HP column 
with an increasing NaCl gradient from 200 mM to 1M prior to buffer exchange with 
the PD-10 column. After buffer exchange, the protein was concentrated, flash 
frozen, and stored at -80°C. 
Protein labeling 
 
Prior to buffer exchange, immobilized metal affinity chromatography (IMAC) 
purified HMPV N0-P was labeled with Alexa 488 TFP ester (ThermoFisher). The 
Alexa 488 TFP ester was prepared with DMSO to make a 10 mg/mL solution. The 
solution was added dropwise to the HMPV N0-P protein sample. The sample 
rocked for 1 hr in the dark. A PD-10 column was used to buffer exchange the 
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sample into 25 mM HEPES, 150 mM KCl, pH 7.5. After buffer exchange, the 
protein was concentrated, flash frozen, and stored at -80°C. Anion exchange 




A 20% dextran solution was prepared in 25 mM HEPES, 150 mM KCl, pH 
7.5. The solution was filter sterilized prior to use. DTT was added to the dextran 
solution to give a final concentration of 1 mM. HMPV protein constructs were 
diluted in the 20% dextran, 1 mM DTT, 25 mM HEPES, 150 mM KCl, pH 7.5 
solution in 1.5 mL Eppendorf tubes. This solution was used in samples for standard 
droplet imaging, fusion droplet imaging, and in turbidity assays. For the HMPV P 
samples tested at different KCl concentrations, similar buffers were prepared with 
KCl ranging from 0 mM to 500 mM. 1.5 µL of sample was plated on an 8-well 
printed microscopy slide and covered with a glass coverslip. For droplets imaged 
at later time points, the slides were stored in a humidified chamber 
Microscopy imaging 
 
HMPV samples were imaged using either DIC or epifluorescence on a 
Nikon Eclipse E600 with the 60X objective. Fusion time lapse images were 
acquired with MetaMorph software using DIC on a Zeiss Axiovert 200M with the 
100X oil objective. Images were acquired at 0.3 sec or 0.5 sec intervals. 
RNA 
 
The fluorescent RNA decamer was purchased from Integrated DNA 
Technologies. It was terminated with OH at the 5’ end and 6-carboxyfluorescein at 
the 3’ end. 
Turbidity assay 
 
Protein solutions were mixed with filter sterilized 20% dextran, 1 mM DTT, 
25 mM HEPES, 150 mM KCl, pH 7.5 in clear 96-well plates. The final concentration 
of the proteins was 40 µM. The absorbance of the solutions was measured on a 
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SpectraMax iD3 at 395 nm (87). Readings were taken at 5 min intervals for 8 hr or 
longer. 
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Chapter 3: Transmembrane Domain Dissociation is Required for Hendra F 
Protein Fusogenic Activity 
 
 
Portions of this chapter were adapted and reprinted with permission from 
the American Society for Microbiology: Slaughter KB, Dutch RE. 2019. 
Transmembrane Domain Dissociation Is Required for Hendra Virus F Protein 





The Paramyxoviridae family consists of negative-sense single-stranded 
RNA viruses enclosed within lipid membranes. Hendra (HeV) and Nipah (NiV) 
viruses, members of the Henipavirus genus, are highly pathogenic zoonotic 
viruses within the Paramyxoviridae family (101). Due to the high mortality rates 
associated with HeV and NiV infections and the lack of a human vaccine or 
effective treatment, they have been designated as biosafety level 4 pathogens 
(102). HeV and NiV were identified in Australia and Malaysia, respectively, in the 
1990s following outbreaks of severe encephalitis and respiratory disease in 
humans (8, 102-104). Further investigation revealed that fruit bats of the 
Pteropodidae family were the natural reservoir for the viruses, and transmission to 
other organisms, including pigs and horses, contributed to the zoonotic spread to 
humans (105-107). The potential for future outbreaks of henipavirus infections and 
the emergence of similar zoonotic viruses warrants further research into the entry 
mechanisms of these pathogens. 
Membrane fusion is an essential step in entry of enveloped viruses that 
relies on the coordination of specialized proteins at the viral membrane surface. 
HeV and NiV possess two surface glycoproteins: the attachment protein (G), which 
allows the virus to bind a target cell, and the fusion protein (F), which promotes 
merger of the viral membrane with the target membrane (108, 109). Both 
glycoproteins, F and G, are required for paramyxovirus membrane fusion, but it is 
still unclear how interactions between F and G and receptor binding promote 
triggering of F (18). The henipaviruses and other members of the Paramyxoviridae 
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family use a trimeric class I F protein to drive membrane fusion (20, 110, 111). 
Before the F protein can participate in fusion events, the inactive precursor (F0) 
must be proteolytically cleaved within the host cell to form a fusion active disulfide- 
linked heterodimer (F1+F2) (FIG 3.1A). For HeV and NiV, the F protein traffics to 
the cell surface and is subsequently endocytosed to be cleaved by the protease 
cathepsin L before being recycled back to the surface (24-26). Following the 
cleavage event, the F protein is maintained at the surface in a metastable prefusion 
state until it is triggered to undergo the conformational changes needed to promote 
membrane fusion. These conformational changes from the prefusion to post-fusion 
form involve an essentially irreversible rearrangement of the F protein ectodomain 
that results in formation of a stable six-helix bundle (FIG 3.1B-F). 
Studies of several viral fusion proteins have shown that the transmembrane 
domain (TMD) is critical for driving fusion events (29, 30, 33-39, 112, 113). For 
HeV, previous work has shown that TMD interactions within the F protein trimer 
help preserve the metastable prefusion conformation and play a role in fusion 
promotion (41, 114, 115). More specifically, these findings suggest that HeV F 
TMD interactions are needed to stabilize the heptad repeat B (HRB) domains that 
form the stalk of the protein prior to triggering (FIG 3.1B). Thus, the current model 
for HeV F fusion events suggests that dissociation of TMD trimeric interactions is 
required to initiate conformational changes that destabilize interactions between 
the HRB domains and eventually promote formation of the post-fusion six-helix 
bundle to drive membrane fusion (41). 
Based on this model, we hypothesized that fusion could be blocked by 
introducing disulfide bonds to covalently link the TMDs of HeV F. Studies using 
substituted cysteine residues to generate disulfide bonds have previously been 
conducted to examine conformational changes in paramyxovirus surface 
glycoproteins. For measles virus (MeV), residues in the attachment protein stalk 
were replaced with cysteine to promote disulfide bond formation to identify four 
conserved residues required for folding into a fusion-conducive conformation 
(116). In addition, studies of the attachment proteins from canine distemper virus 
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and MeV showed that introduced disulfide bonds in the central region of the stalk 
blocked fusion, but fusion activity was restored under reducing conditions (117). 
For the Newcastle disease virus attachment protein, disulfide bonds were 
generated across the dimer interface in the globular domain to show changes in 
receptor binding and fusion promotion (118). 
Introduced disulfide bonds have also been an important tool for studying 
paramyxovirus F proteins. Single cysteine substitutions were made in the 
membrane-proximal region of the heptad repeat B (HRB) domain of MeV F, 
generating disulfide-linked dimers, to study formation of the post-fusion six-helix 
bundle. Results showed that the constructs were able to promote efficient viral 
entry even though two HRB domains were locked together by a disulfide bond 
(119). Other studies have used double cysteine substitutions to further restrict 
conformational changes in the paramyxovirus F protein. For MeV F, introduced 
disulfide bonds that linked the globular head and stalk domain of different 
monomers within the F trimer blocked fusion activity, and fusion was partially 
restored by subsequently reducing the disulfide bridges. These findings suggested 
that fusion activity requires reversible interactions between the stalk and head 
domains of the F protein (120). For PIV5 F, double cysteine substitutions were 
used to introduce disulfide bonds in the membrane-proximal external region 
(MPER) which is N-terminal to the TMD. Results from this study showed that 
dissociation of the MPER region within the PIV5 F trimer is necessary to promote 
the conformational changes that drive fusion events (121). Additionally, work on 
HeV F used double cysteine substitutions to block conformational changes in the 
ectodomain to analyze effects on fusion. This study showed that introduced 
disulfide bonds in the ectodomain could inhibit fusion by stabilizing HeV F in the 
prefusion conformation (122). 
Previous evidence and calculations for paramyxoviruses have shown that 
the TMDs of the F protein are potentially longer than a typical vertically inserted 
membrane-spanning helix (112). Due to the lack of structural data for membrane- 
spanning regions, the orientation of the paramyxovirus F protein TMDs within the 
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membrane remains unclear. We selected residues near the N-terminal region of 
the predicted HeV F TMD for substitution with double cysteine residues to 
determine if TMD dissociation is essential to drive conformational changes 
required for fusion events (FIG 3.1A). These TMD mutants were designed with the 
goal of introducing disulfide bonds that would link the three monomers of the F 
trimer in the TMD region to assess alterations in fusion activity, protein stability, 
and overall protein conformation. 
Double cysteine substitutions in the HeV F TMD led to the formation of 
disulfide-linked trimers, and fusion was blocked for these mutants. Attempts to 
restore fusion for the mutants with a disulfide reducing agent were unsuccessful, 
suggesting that the introduced disulfide bonds were protected in the membrane. 
Further analysis showed that two of the mutants were expressed at the cell surface 
in the prefusion conformation at levels that would normally promote fusion. Our 
results suggest that these two mutants were properly folded and processed, 
supporting the conclusion that TMD dissociation is required for fusion promotion. 
This study is the first to show that HeV F fusogenic activity can be prohibited by 
blocking TMD dissociation. These findings provide important new information on 
paramyxovirus fusion and contribute to our current knowledge of HeV F TMD 





Double cysteine substitutions in the HeV F TMD promote disulfide bond 
formation 
Our current model suggests that TMD dissociation is important for 
conformational changes in the ectodomain needed for fusion, so substitutions were 
made in the HeV F TMD to analyze the effects on protein folding, stability, and 
fusion promotion when the TMDs are locked together. HeV F associates as a 
homotrimer immediately following synthesis, so double cysteine substitutions were 
made to link the three monomers with disulfide bonds (T483C/V484C, 
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V484C/N485C, N485C/P486C). The mutation locations were selected based on 
the prediction that the residues were present in the N-terminal region of the HeV F 
TMD. HeV F is synthesized in the endoplasmic reticulum (ER) which has a thinner 
lipid bilayer than the plasma membrane (123). Our goal was to mutate residues in 
the TMD that could be exposed to the oxidizing environment of the ER to allow for 
disulfide bond formation before trafficking to the cell surface. 
The oligomeric state of the HeV F TMD mutants was analyzed to determine 
if disulfide bonds successfully linked the monomers of the HeV F trimer. Vero cells 
were transiently transfected with plasmids encoding WT HeV F or one of the TMD 
mutants. Then, cells were starved, metabolically labeled, and samples 
immunoprecipitated using an anti-peptide antibody that binds to the cytoplasmic 
tail of HeV F. Boiled samples were separated on 3.5% polyacrylamide gels under 
non-reducing conditions to allow for visualization of different oligomeric forms of 
HeV F. T483C/V484C, V484C/N85C, and N485C/P486C migrated primarily in the 
trimeric form, whereas WT HeV F migrated primarily as a monomer (FIG 3.2A). 
This suggested that the double cysteine substitutions in HeV F resulted in disulfide 
bonds that covalently linked the monomers of the HeV F trimer. In contrast, WT 
HeV F migrated primarily in the monomeric form because the monomers of the 
trimer lack covalent interactions. To confirm that the trimeric form was a result of 
introduced disulfide bonds, samples were alternatively treated under reducing 
conditions. Results showed that the HeV F TMD mutants migrated in the 
monomeric form, similar to WT HeV F, under reducing conditions (FIG 3.2B). 
Taken together, these findings indicate that the monomers of T483C/V484C, 
V484C/N85C, and N485C/P486C were effectively cross-linked due to the 
introduction of disulfide bonds between the TMDs of the F trimer. 
Fusogenic activity is blocked for the HeV F TMD mutants 
 
Fusion assays were conducted to determine whether the mutants could 
promote fusion when TMD dissociation was inhibited. Vero cells were transiently 
transfected with plasmids encoding WT HeV G and WT HeV F or one of the TMD 
mutants. Cells transfected with WT HeV G alone or empty vector served as 
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negative controls. At 48 hr post-transfection, the cells were analyzed by 
microscopy for syncytia formation. As expected, cells transfected with a 
combination of WT HeV F and G showed the formation of small and large syncytia 
(FIG 3.3A). However, samples transfected with WT HeV G and one of the TMD 
mutants showed no syncytia formation, suggesting that the introduced disulfide 
bonds blocked normal fusion promotion (FIG 3.3A). 
A quantitative luciferase reporter gene assay was used to confirm the 
syncytia assay results. Vero cells were transiently transfected with plasmids 
encoding luciferase under the control of a T7 promoter, WT HeV G, and WT HeV 
F or one of the TMD mutants. At 24 hr post-transfection, the Vero cells were 
overlaid with BSR cells containing the T7 polymerase. After a 3 hr incubation, the 
cells were lysed and analyzed for luminescence as a measure of cell-cell fusion. 
Results showed that the TMD mutants did not promote fusion above the levels 
observed for the negative control (HeV G alone). Together, these results indicate 
that introduced disulfide bonds in the HeV F TMD prohibit fusion activity. 
Cell surface expression is variably reduced for the HeV F TMD mutants 
 
Previous studies have shown that increased cell surface density of WT HeV 
F correlates with increased fusion activity (124). Cell surface expression analysis 
was performed to determine if the TMD mutants were trafficked to the surface at 
levels that would normally allow for fusion promotion. Vero cells were transiently 
transfected with WT HeV F or one of the TMD mutants, starved, and metabolically 
labeled. Then, the samples were biotinylated prior to lysis and immunoprecipitation 
so that the cell surface protein population could be isolated and compared to total 
protein levels via SDS-PAGE analysis. Results for total protein expression showed 
no significant differences for the TMD mutants compared to WT HeV F (FIG 3.4A, 
3.4C), whereas protein cleavage was significantly reduced for the mutants (FIG 
3.4D), indicating they may be processed and trafficked less efficiently. Analysis of 
cell surface protein expression and cleavage showed significantly reduced levels 
for N485C/P486C, suggesting that this mutant may be misfolded or have severe 
trafficking defects (FIG 3.4B, 3.4E). Similar to total protein cleavage results, 
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surface protein cleavage levels for the TMD mutants were significantly reduced, 
further indicating that they are trafficked and processed less efficiently than WT 
HeV F (FIG 4F). Although T483C/V484C and V484C/N485C cleavage was 
reduced, the amount of fusion active F1 on the surface was above the level 
previously shown to be needed for HeV F fusion (124). Based on these results, 
T483C/V484C and V484C/N485C are likely unable to promote fusion because 
TMD dissociation is an essential step for initiating conformational changes during 
fusion events. 
T483C/V484C and V484C/N485C are maintained over time at levels that 
normally allow for fusion 
Since the HeV F TMD mutants showed moderate differences in total 
expression and variable differences in surface expression compared to WT HeV 
F, a time course immunoprecipitation experiment was performed to monitor 
stability of the F protein over time (FIG 3.5). Vero cells were transiently transfected 
with WT HeV F or one of the TMD mutants. Then, the cells were starved, 
metabolically labeled, and chased with regular media for different amounts of time, 
as indicated. Finally, cells were lysed and samples immunoprecipitated for SDS- 
PAGE analysis. At early time points, WT HeV F and the TMD mutants were 
predominantly found in the F0 inactive form (FIG 3.5A). Over time, levels of the F1 
proteolytically active form increased, indicating that WT HeV F and the mutants 
were processed. Interestingly, quantification of expression levels at different time 
points showed that the mutants were highly expressed compared to WT HeV F at 
early time points (FIG 3.5B). At later times, T483C/V484C and V484C/N485C 
showed reductions in protein levels compared to WT HeV F, indicating that these 
mutants may have minor folding changes that target some of the protein for 
degradation. However, N485C/P486C showed a more severe reduction in protein 
level over time, suggesting that this mutant is likely targeted for degradation after 
synthesis due to improper folding. This result is consistent with the finding that 
N485C/P486C surface expression was significantly reduced (FIG 3.4). Overall, 
these results show that the location of introduced disulfide bonds in the HeV F 
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TMD can variably affect protein folding and stability over time. These findings 
suggest the minor changes observed for T483C/V484C and V484C/N485C protein 
stability are likely not the cause of fusion prohibition. 
Introduced disulfide bonds in the HeV F TMD mutants are poorly accessible 
to reducing agent 
Since fusion assays with the TMD mutants suggested that TMD dissociation 
is essential for fusion promotion, the mutants were analyzed to determine if fusion 
could be restored by reducing the introduced disulfide bonds. In theory, reduction 
of the disulfide bonds linking the TMDs would allow for dissociation of the TMDs 
to initiate the necessary conformational changes in the ectodomain for fusion 
activity. To test this, a luciferase reporter gene assay was conducted as described 
previously, except that the overlay media contained the cell-impermeant reducing 
agent tris(2-carboxyethyl)phosphine (TCEP). Following the 3 hr incubation with 
overlaid BSR cells in 6 mM TCEP-containing media, the samples were analyzed 
for luminescence. Interestingly, fusion increased for WT HeV F treated with TCEP, 
suggesting that reduction of intramolecular disulfide bonds may impact overall 
protein stability and enhance triggering (FIG 3.6A). However, results for the TMD 
mutants showed no significant change in fusion levels between treated and 
untreated samples, indicating that fusion was not restored in the presence of TCEP 
(FIG 3.6A). 
Oligomeric analysis was performed to further understand the effects of 
TCEP on the introduced disulfide bonds in the TMD mutants. The samples were 
prepared as described in FIG 3.2, except a 3 hr incubation with 6 mM TCEP or 
untreated media was included after the metabolic label. Then, samples were 
immunoprecipitated and analyzed by SDS-PAGE. Interestingly, results of the 
analysis showed that TCEP was capable of reducing disulfide bonds within the WT 
F protein, as indicated by the shift in bands for the trimer, dimer, and monomer in 
treated samples (FIG 3.6B). This shift is consistent with loss of the extracellular F2 
subunit when F1+F2 is reduced in the presence of TCEP. The TMD mutants also 
showed shifts consistent with loss of the F2 subunit (FIG 3.6B, asterisks). 
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T483C/V484C showed some reduction from the trimeric to monomeric form, but a 
portion of the trimeric form was still present in the TCEP-treated samples. The 
trimeric form of V484C/N485C partially shifted to a trimer lacking F2 in the TCEP- 
treated samples, but there was little change in the amount of monomer. The 
oligomeric forms of N485C/P486C remained relatively unchanged following TCEP 
treatment. This indicates that TCEP was poorly able to access the introduced 
disulfide bonds linking the TMDs of the mutant HeV F proteins, and accessibility 
decreased as the mutations went further into the TMD region. Altogether, this data 
suggests that the introduced disulfide bonds in the mutants are likely buried in cell 
membrane, making them, in some cases, inaccessible to the reducing agent. 
T483C/V484C and V484C/N485C bind a prefusion conformation-specific 
antibody prior to cell disruption 
Since T483C/V484C and V484C/N485C were present at the cell surface at 
levels that would allow for fusion, further studies were conducted to analyze the 
conformation of the mutant protein structures. A HeV F prefusion conformation- 
specific antibody, mAb 5B3, was used to compare WT HeV F to the TMD mutants 
(100, 122). Vero cells were transiently transfected with WT HeV F or one of the 
mutants. At 24 hr post-transfection, the cells were metabolically labeled overnight 
and treated with the prefusion antibody prior to cell lysis and immunoprecipitation. 
Control samples were treated with the HeV F anti-peptide antibody after cell lysis. 
Results showed that T483C/V484C and V484C/N485C were able to bind the 
prefusion conformation-specific antibody at moderately reduced levels compared 
to WT HeV F (FIG 3.7A, 3.7B). This result is consistent with the cell surface protein 
expression levels observed for T483C/V484C and V484C/N485C, suggesting that 
the TMD mutants trafficked to the surface are present in the prefusion form (FIG 
3.4). 
Prior work with the prefusion conformation-specific antibody has shown that 
WT HeV F is unable to bind the antibody when it is applied following cell lysis, likely 
due to disruption of the metastable prefusion conoformation of HeV F following 
lysis buffer treatment. Since the TMDs of T483C/V484C and V484C/N485C are 
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locked together by disulfide bonds, these mutants were tested to determine if the 
introduced disulfide bonds permanently lock the prefusion conformation of the 
ectodomain. The HeV F TMD mutants were tested with mAb 5B3 after cell lysis to 
analyze prefusion conformation-specific antibody binding, and results showed that 
treating the mutants with mAb 5B3 following cell disruption dramatically reduced 
levels of binding (FIG 3.7C). Together, these results suggest that T483C/V484C 
and V484C/N485C are synthesized in a prefusion conformation, but locking the 






The model for HeV fusion suggests that dissociation of the F protein TMDs 
is an essential step for initiating and completing conformational changes in the 
ectodomain required for membrane fusion (41). We tested this model by designing 
HeV F TMD mutants to introduce disulfide bonds that would link the TMDs and 
prevent trimeric dissociation. Results showed that the mutants were successfully 
synthesized as disulfide-linked trimers, but fusion was prohibited for the mutants, 
suggesting that TMD dissociation is critical for the conformational changes in HeV 
F needed for fusion. Whereas surface expression and stability of T483C/V484C 
and V484C/N485C were maintained at levels that would allow for fusion, our 
results showed that N485C/P486C surface expression was significantly reduced, 
suggesting that the position of these introduced disulfide bonds interfered with 
proper protein folding. Attempts to restore fusion for the TMD mutants were 
unsuccessful, indicating that the introduced disulfide bonds were poorly accessible 
to the reducing agent due to their position in the membrane. Additional analysis of 
the TMD mutants showed that T483C/V484C and V484C/N485C were maintained 
in a prefusion conformation prior to cell disruption. Together, these findings support 
the hypothesis that TMD dissociation is required for HeV fusogenic activity and 
that TMD interactions play a crucial role in F protein folding and stability. 
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Cleavage of the HeV F TMD mutants was significantly reduced compared 
to WT HeV F, which could contribute to the lack of fusion. Previous work from our 
lab showed that decreased WT HeV F expression leads to decreased fusion 
activity, but fusion was still detectable when normal WT HeV F surface expression 
was reduced by 80 percent (124). The amount of active F1 protein at the surface 
for the mutants T483C/V484C and V484C/N485C was above that needed for 
fusion for the WT protein. However, our reporter gene assay results showed no 
fusion above background levels for the HeV F TMD mutants, supporting our 
conclusion that fusion is blocked. 
Previous work with other paramyxoviruses has utilized introduced disulfide 
bonds to probe the effects of limiting mobility within the F protein. For PIV5, 
introduced disulfide bonds that linked the monomers within the MPER, N-terminal 
to the predicted TMD, blocked fusion activity (121). This was consistent with the 
inhibition of fusion observed for the HeV F TMD mutants. Treatment of the PIV5 F 
MPER mutant with TCEP restored fusion activity. However, similar treatment of 
the HeV F TMD mutants with TCEP did not restore fusion. This suggests that the 
disulfide bonds of the HeV F TMD mutants in this story were protected in the 
membrane, whereas the MPER disulfide bonds in the PIV5 F mutant were exposed 
at the cell surface (121). 
Additional work related to PIV5 F has addressed the role of the TMD in 
fusion. Investigations showed that single cysteine substitutions near the N- 
terminus of the TMD led to disulfide bond formation in the absence of an oxidative 
cross-linker, similar to the disulfide bond formation we observed in the HeV F TMD 
mutants (112). Further analysis of this region of PIV5 F using alanine-scanning 
mutagenesis indicated that two residues, L486 and I488, were required for efficient 
fusion activity. Different amino acids were substituted at these sites to test the 
effects of amino acid side chains on fusion activity. Interestingly, substitution with 
cysteine led to a minor reduction in fusion activity compared to the severe 
reductions observed with other substitutions. This finding is consistent with the 
idea that disulfide bond formation, rather than the presence of substituted cysteine 
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residues, drove the prohibition of fusion activity for the HeV F TMD mutants. In 
addition, an alanine substitution was previously made at residue 486 in HeV F, 
resulting in minimal changes in fusion activity compared to WT, further suggesting 
that disulfide bond formation, rather than the cysteine substitutions, played a key 
role in blocking fusion activity for the HeV F TMD mutants (Barrett, Popa, 
unpublished data). 
Single cysteine substitutions were also used in a study to examine 
conformational changes in MeV F. They generated disulfide-linked mutants that 
were predicted to be unable to fully close the six-helix bundle (119). The single 
substitutions were made near the membrane-spanning region in the HRB domain. 
Despite this restriction on F protein flexibility, the mutants were able to efficiently 
open and stabilize fusion pores for viral entry, suggesting that these fusion events 
occur independently of complete six-helix bundle assembly (119). This work 
indicates that these single cysteine substitutions allow for greater flexibility than 
double cysteine substitutions in the membrane-proximal region of the F protein and 
provide evidence to support the idea that flexibility of interactions in the HRB and 
TMD are required for efficient fusion activity. 
When TCEP was used in an attempt to restore fusion activity in our study, 
results showed that fusion was enhanced for WT HeV F. This increase may be 
due to the reduction of other disulfide bonds within the ectodomain of HeV F that 
are required for prefusion stability. Work on Newcastle disease virus identified free 
thiols in the surface-expressed F protein, a result of thiol/disulfide-exchange, and 
blocking these groups with a thiol-specific biotin inhibited fusion (125). 
Thiol/disulfide-exchange also plays a role in the entry of other enveloped viruses 
such as human immunodeficiency virus type I (126). These findings suggest that 
reduction of specific disulfide bonds in the F protein of paramyxoviruses may affect 
the efficiency of fusion activity. For HeV F, reducing disulfide bonds in the 
ectodomain by adding TCEP may cause the protein to trigger and promote fusion 
more readily than untreated HeV F. The HeV F TMD mutants showed small 
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increases in fusion following TCEP treatment. However, these changes in fusion 
activity were not significant when compared to the untreated mutants. 
The paired cysteine substitutions we made in HeV F were located near the 
N-terminus of the TMD, but our results suggested that the introduced disulfide 
bonds were buried within the plasma membrane. The F protein is synthesized in 
the ER which consists of a slightly thinner lipid bilayer than the plasma membrane 
(123). This difference in membrane thickness may be important for exposing the 
N-terminal region of the HeV F TMD to the oxidizing environment of the ER to allow 
for disulfide bond formation immediately following synthesis. Once the mutant HeV 
F proteins are trafficked through the secretory pathway to the thicker plasma 
membrane, the disulfide bonds in the TMD may be shielded by the lipid 
environment from extracellular factors that could be introduced to disrupt the 
bonds. 
Membrane thickness is largely determined by lipid composition, and a 
number of membrane lipids have been identified as important players in viral 
infectivity (127-133). Additionally, several studies of non-viral proteins have shown 
that cholesterol and sphingolipids play a role in promoting TMD helix interactions 
(134-136). Work with the paramyxovirus MeV has shown that the F protein is 
enriched in lipid rafts, and this partitioning is important for MeV assembly at the 
plasma membrane (132). Studies of NiV have shown evidence of F protein 
clustering in the plasma membrane, suggesting that membrane domains may be 
needed for proper surface glycoprotein organization for assembly and fusion (137). 
For Newcastle disease virus, lipid rafts have been shown to participate in forming 
and maintaining F protein and attachment protein complexes in the plasma 
membrane (138). Beyond paramyxoviruses, lipid rafts domains have been 
implicated in the assembly and spread of filoviruses, retroviruses, and 
orthomyxoviruses (139). It is possible that lipid rafts also play a role in HeV 
assembly and TMD helix interactions. Additionally, partitioning of the F protein into 
rafts could increase the number of TMD residues accommodated by the 
membrane. Therefore, HeV F localization to lipid rafts could explain why the 
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introduced disulfide bonds are initially formed at the ER but are protected from 
reducing agents at the plasma membrane. Future studies will analyze the 
importance of lipid composition for stability of the prefusion conformation and 
promotion of fusion events. 
Here, we showed that disulfide bonds can be introduced to covalently link 
the TMDs of the HeV F trimer. Blocking TMD dissociation with introduced disulfide 
bonds prohibits fusion events, but further studies are needed to address the 
conformational changes that can occur in HeV F when the TMDs are locked. Our 
studies suggest that mutant HeV F proteins with linked TMDs are in some cases 
capable of maintaining a prefusion conformation. If cells expressing these 
constructs are disrupted, then the mutant HeV F proteins refold into a conformation 
that is no longer recognizable by a prefusion specific antibody. Additional analysis 
is needed to understand if the disulfide-linked HeV F mutants are capable of 
refolding into protein intermediates that are suggested to occur after an initial 
triggering event and prior to formation of the six-helix bundle. Our findings reported 
here and future studies will contribute to understanding HeV F dynamics required 





Figure 3.1. HeV F protein schematic and fusion model. (A) Diagram of the 
fusion-active, disulfide (S-S)-linked F protein with the HeV F TMD sequence below. 
Domain structure includes the fusion peptide (FP), heptad repeat A (HRA), HRB, 
TMD, and the cytoplasmic tail (CT). In the fusion model, the TMDs of the 
metastable prefusion F interact as a trimer (B). Then triggering of F leads to 
dissociation of the TMDs and the HRB domains (C). Changes in TMD interactions 
promote extension of the HRA domains and insertion of the FP into the target 
membrane (D). (E and F) Further refolding of F leads to formation of the postfusion 




Figure 3.2. Double cysteine substitutions in the HeV F TMD promote disulfide 
bond formation. Vero cells were transfected with WT HeV F or one of the TMD 
mutants. At 24 h posttransfection, the cells were metabolically labeled for 3 h, and 
samples were immunoprecipitated. WT HeV F and the mutants were treated with 






Figure 3.3. Fusogenic activity is blocked for the HeV F TMD mutants. (A) Vero 
cells were transfected with the attachment protein WT HeV G and WT HeV F or 
one of the TMD mutants. Syncytium formation was analyzed at 48 h 
posttransfection. Images were taken with a Zeiss Axiovert 100 microscope. White 
arrowheads indicate syncytia. Images are representative. (B) Vero cells were 
transfected with luciferase, WT HeV G, and WT HeV F DNA or one of the TMD 
mutants. At 24 h posttransfection, the Vero cells were overlaid with BSR cells. After 
a 3-h incubation period, the cells were lysed and prepared for luminosity analysis 
to quantify fusion. Results were normalized to samples transfected with WT HeV 
F and G. All data are presented as the means ± standard deviations for three 
independent experiments. Statistical analysis was performed using a two-way 
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analysis of variance with a Bonferroni correction. Asterisks indicate statistical 





Figure 3.4. Cell surface expression is variably reduced for the HeV F TMD 
mutants. Total (A) and surface (B) expression levels were analyzed using a 
biotinylation method. Vero cells were transfected with WT HeV F or one of the TMD 
mutants. At 24 h posttransfection, the cells were metabolically labeled for 4 h, 
followed by biotinylation of the surface proteins and immunoprecipitation. The 
samples were analyzed by 15% SDS-PAGE. Total expression (F0+ F1) and 
cleavage [F1/(F0+F1)] (C and D), as well as surface expression and cleavage (E 
and F) were quantified by densitometry and normalized to levels for WT HeV F. All 
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data are represented as the means ± standard deviations for three independent 
experiments. Statistical analyses were performed using a two-way analysis of 
variance with a Bonferroni correction. Asterisks indicate statistical significance 




Figure 3.5. T483C/V484C and V484C/N485C are present over time at levels 
that normally allow for fusion. (A) Vero cells were transfected with WT HeV F or 
one of the TMD mutants. At 24 h posttransfection, the cells were metabolically 
labeled for 30 min. Following different chase time points, the samples were 
immunoprecipitated and analyzed by 10% SDS-PAGE. (B) Expression was 
quantified by densitometry and normalized to the value for WT HeV F at each time 





Figure 3.6. The introduced disulfide bonds in the HeV F TMD mutants are 
poorly accessible to reducing agent. (A) The samples were prepared as 
described in the legend of Fig. 3B, except the overlay medium consisted of BSRs 
in DMEM plus 10% FBS ± 6 mM TCEP. Results were normalized to levels of the 
samples transfected with WT HeV F and G (untreated). All data are presented as 
the means ± standard deviations for three independent experiments. Statistical 
analysis was performed using two-way analysis of variance with a Bonferroni 
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correction. Asterisks indicate statistical significance compared to the level of the 
WT HeV F+G (untreated) (***, P < 0.005). (B) The samples were prepared as 
described in the legend of Fig. 2A, except that the samples were treated with 
DMEM plus 10% FBS ± 6 mM TCEP for 3 h following the metabolic label. Blue 
asterisks indicate trimer (F1), purple asterisk indicates dimer (F1), and orange 





Figure 3.7. T483C/V484C and V484C/N485C bind a prefusion conformation- 
specific antibody prior to cell disruption. (A) Vero cells were transfected with 
WT HeV F or one of the TMD mutants. At 24 h posttransfection, the cells were 
metabolically labeled for 24 h. Then, the cells were treated with HeV F MAb 5B3 
antibody for 1 h, followed by lysis and pulldown. Control samples were lysed after 
the overnight label and treated with HeV F anti-peptide Ab for immunoprecipitation. 
The samples were analyzed by 10% SDS-PAGE. (B) 5B3 binding was quantified 
by densitometry and normalized to the level of WT HeV F. All data are represented 
as the means ± standard deviations for three independent experiments. (C) Vero 
cells were transfected with WT HeV F or one of the TMD mutants. At 24 h 
posttransfection, the cells were metabolically labeled for 3 h. Then, the samples 
were immunoprecipitated with anti-peptide Ab or MAb 5B3 and analyzed by 10% 
SDS-PAGE. 
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Chapter 4: Human Metapneumovirus Replication Proteins Phase Separate 





Human metapneumovirus (HMPV), which was discovered in 2001, is a 
leading cause of severe respiratory tract infections in infants, the elderly, and 
immunocompromised individuals (140). Five to twenty percent of hospitalizations 
from respiratory infections in young children are due to HMPV (141, 142). 
Symptoms of HMPV infection are similar to respiratory syncytial virus (RSV) and 
include fever, cough, rhinorrhea, croup, bronchiolitis, pneumonia, and asthma 
exacerbation (143). HMPV and RSV are members of the Pneumoviridae family 
which was created in 2016 and classified within the Mononegavirales order (42). 
Currently, no vaccines or antiviral treatments are approved to treat HMPV 
infections, so most patients are managed with supportive care (143). The recent 
discovery of HMPV highlights the need to understand the basic mechanisms of its 
infectious life cycle. Specifically, analyzing the process of HMPV replication may 
be crucial for identifying new targets for antiviral development. 
Along with the pneumoviruses HMPV and RSV, other disease-causing 
pathogens within the Mononegavirales order include Ebola virus, measles virus 
(MeV), and rabies virus (RABV), which have negative-sense, single-stranded RNA 
genomes. Though these viruses are classified within different families, they have 
all been reported to form membrane-less cytoplasmic structures within infected 
cells known as inclusion bodies (IBs) (58, 59, 61, 64). For some negative-sense, 
single-stranded viruses, including HMPV, IBs have been shown to house active 
viral replication and transcription (56, 57, 66-73). These processes involve several 
viral proteins, such as the large polymerase (L), phosphoprotein (P), and 
nucleoprotein (N). Further analysis of these structures has shown that RSV, MeV, 
RABV, and vesicular stomatitis virus (VSV) IBs possess the properties of liquid 
organelles formed via liquid-liquid phase separation (LLPS) (66, 85-88). LLPS is a 
biophysical process by which a homogenous fluid separates into two distinct liquid 
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phases (81). Phase separation plays a role in the formation of a variety of 
membrane-less cellular compartments, such as processing bodies (P-bodies), 
stress granules, and nucleoli, to concentrate specific proteins and nucleic acids, 
particularly RNA (83). Properties that define these structures as liquid organelles 
include the ability to undergo fusion and fission, rapid diffusion of internal contents, 
and a spherical shape due to surface tension (144). Though LLPS has been shown 
to play a role in the formation of IBs for some viruses, the physical mechanisms 
and materials that mediate this process in the viral life cycle are still poorly 
understood. 
For RSV, HMPV, MeV, and RABV, the minimum viral components required 
to reconstitute IB-like structures in cells are the N protein, which encapsidates the 
RNA genome, and the P protein, which acts as a cofactor to mediate interactions 
between the nucleoprotein and polymerase (65, 66, 75, 86). VSV also requires the 
presence of the L protein with the N and P proteins to form IBs (85).These findings 
suggest that interactions between the N and P proteins regulate phase separation 
to form IBs as a structural platform for viral replication and transcription. Most 
studies thus far have focused on cellular experiments to investigate viral IB liquid 
dynamics, but recent publications on MeV and RSV have shown the importance 
of utilizing purified protein systems to analyze interactions between the N and P 
proteins in vitro (87, 88) . For MeV, the purified P protein and monomeric N protein 
failed to phase separate independently but formed liquid droplets when mixed, 
similar to the requirements for IB formation observed in cells. Interestingly, when 
RNA was added to MeV N/P liquid droplets, it incorporated into the droplets and 
led to the formation of nucleocapsid-like particles that were detected by electron 
microscopy (87). In vitro experiments with RSV proteins showed that RNA-bound 
N protein rings and P protein form phase separated liquid droplets when combined 
in solution (88). These findings support the model that viral IBs form via LLPS, and 
this mechanism is highly dependent upon interactions between the N and P 
proteins. This process may enhance viral replication transcription for RSV. 
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This is the first report to analyze phase separation for HMPV IBs. The HMPV 
life cycle begins with the virus attaching and fusing to a target cell to release its 
nucleocapsid into the cytoplasm with the associated replication proteins. The 
nucleocapsid structure protects the genome from host nucleases and acts as a 
template for the L protein. The genome is used to generate viral mRNA transcripts 
that are translated by the host cell ribosomal machinery. The genome is also 
replicated to make antigenome copies that can then be used to generate more 
negative-sense genome to package into new virions. The P protein acts as an 
adaptor to regulate interactions between the polymerase and RNA template during 
transcription and replication. It functions as a tetrameric protein, in which the 
monomers interact through a central oligomerization domain (84, 145). The 
oligomerization domain is flanked by large intrinsically disordered regions (IDRs) 
that give HMPV P the ability to interact with a variety of binding partners (84). For 
instance, the C-terminus of the P protein interacts with RNA-bound N protein to 
chaperone attachment to the polymerase. Additionally, HMPV P maintains a 
monomeric pool of unbound N protein (N0) through an interaction involving the 
HMPV P N-terminus with the C-terminal domain of the N protein (47). The 
monomeric N0 protein can then be used for nucleocapsid assembly at sites of 
replication where the polymerase synthesizes nascent RNA (47). HMPV P also 
recruits the antitermination factor M2-1 to the polymerase during transcription to 
bind nascent viral mRNA (99). Beyond transcription and replication, HMPV P has 
been shown to play a role in direct cell-to-cell spread of infection by interacting with 
actin, or an actin-binding protein, to reorganize the host cell cytoskeleton (76). 
During HMPV infection, incoming and newly synthesized nucleocapsids 
concentrate together in the cytoplasm in an actin-dependent manner (56, 74). 
Eventually, the coalescence of these structures induces the formation of IBs where 
viral RNA, viral mRNA, P protein, and N protein are detected (56). Inhibition of 
actin polymerization was shown to significantly reduce HMPV viral transcription 
and replication, suggesting that IB coalescence enhances the efficiency of these 
processes (56). Recent work from our lab has shown that HMPV IBs are dynamic 
structures that undergo fusion and fission in cells (Cifuentes-Muñoz, unpublished 
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data). In addition, fluorescence recovery after photobleaching (FRAP) analysis has 
shown that the internal contents of HMPV IBs have diffusion rates consistent with 
other membrane-less compartments (El Najjar, unpublished data). Together, these 
results support the characterization of HMPV IBs as liquid organelles formed by 
LLPS. 
Here we utilize a purified protein system to analyze LLPS of HMPV proteins 
in vitro to support the characterization of HMPV IBs as liquid organelles and to 
determine the interactions required for phase separation. We report that HMPV N 
and P undergo phase separation and colocalize within liquid droplets when they 
are mixed in solution. In contrast to MeV and RSV, the HMPV P protein undergoes 
phase separation in the absence of other protein binding partners in vitro. RNA 
localizes to HMPV P liquid droplets, providing the first evidence that HMPV P 
interacts directly with RNA. A heparin purified N0-P construct, consisting of full- 
length N protein linked to the first 40 amino acids of P, also phase separated 
independently. However, combining N0-P with RNA led to the formation of solid 
aggregates, suggesting that the addition of RNA promotes a liquid-to-solid 
transition. WT RNA-bound N protein rings formed aggregates in solution but 
incorporated into liquid droplets in the presence of P protein. These findings 
suggest that HMPV P acts as a scaffold protein to support multivalent interactions 




HMPV P phase separates independently in vitro 
Since the HMPV N and P proteins are the minimum requirements needed 
to form IB-like structures in eukaryotic cells, recombinant versions of the proteins 
were expressed in E. coli and purified for in vitro analysis. Full-length, His6-tagged 
HMPV P was purified by immobilized metal affinity chromatography (IMAC) 
followed by anion exchange chromatography. Purified HMPV P was then tested in 
the presence of the crowding agent dextran to assess its ability to undergo LLPS. 
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LLPS is typically driven by scaffold proteins with specific features that promote 
multivalent interactions with other proteins or RNA (80, 146, 147). HMPV P, which 
includes long IDRs and alternating charged regions, fits the criteria of an LLPS 
scaffold protein (84). Unlike the reports for MeV and RSV, purified HMPV P formed 
liquid droplets independently that were visualized using differential interference 
contrast (DIC) microscopy (FIG 4.1A). Time lapse imaging of the HMPV P droplets 
showed that they underwent fusion, consistent with the idea that they possess a 
liquid nature (FIG 4.1B). A turbidity assay was also used to analyze purified HMPV 
P phase separation. The absorbance of the purified HMPV P protein solution was 
measured at 395 nm at different time points to detect LLPS. The measurements 
showed a peak for the absorbance above 0.12 between two and four hours, 
supporting the microscopy imaging results that HMPV P phase separates in the 
absence of other protein binding partners (FIG 4.1C). 
Interactions with nucleic acid modulate HMPV P phase separation dynamics 
 
Using the protein purification protocol described above, we noticed that the 
A260/280 ratio was around 1.08, suggesting that the HMPV P protein sample was 
interacting with nucleic acid. Since nucleic acids are known to play a role in LLPS, 
we utilized an alternative purification protocol to determine if removing the nucleic 
acid would influence HMPV P liquid droplet formation. The alternative protocol 
included treatment with Benzonase nuclease and a IMAC purification step followed 
by a heparin affinity column purification. This method was successful in removing 
some of the nucleic acid as indicated by the decreased A260/280 ratio of 0.85. 
Interestingly, DIC microscopy analysis showed that the recombinant HMPV P 
protein purified by our alternative protocol formed liquid droplets more robustly 
than the original protein sample (FIG 4.2A). In addition, time lapse imaging 
analysis showed that the liquid droplets were capable of fusing (FIG 4.2B). 
Turbidity assay results for the heparin purified HMPV P protein were similar to 
previous samples, with a peak above 0.12 between two and four hours (FIG 4.2C). 
These results suggest that the presence of increased levels of nucleic acid 
modulate HMPV P phase separation dynamics. 
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Charge interactions are known to influence phase separation and nucleic 
acid binding, so both versions of purified HMPV P (anion exchange purified and 
heparin purified) were analyzed for liquid droplet formation using buffers with 
different concentrations of potassium chloride (KCl) ranging from 0 to 500 mM. For 
the anion exchange purified HMPV P, liquid droplets were easily detected between 
150 and 250 mM KCl. However, droplet formation was inhibited at concentrations 
below or above that range (FIG 4.3A). For the heparin purified HMPV P, the largest 
droplets formed at 150 mM KCl (maximum droplet size >50 µm). However, unlike 
the anion exchange purified sample, liquid droplets formed for all the KCl buffers 
tested (FIG 4.3A). This result suggests that HMPV P protein samples containing 
higher levels of nucleic acid are more sensitive to changes in charge, thus leading 
to the disruption of liquid droplet formation in vitro. 
The differences we observed for anion exchanged purified and heparin 
purified HMPV P led us to hypothesize that the multifunctional HMPV P protein 
also possesses the ability to bind RNA. Given that 35 percent of the HMPV P 
sequence consists of charged amino acids, it is not surprising that contaminating 
RNA from E. coli may bind to HMPV P during the expression and purification 
process (84). Based on our idea that HMPV P serves as a scaffold protein to drive 
phase separation and recruit other viral components to IBs, we tested purified 
HMPV P with a fluorescently tagged RNA oligomer to determine if RNA would 
localize to the liquid droplets. Fluorescence imaging showed that the RNA oligomer 
was incorporated into HMPV P liquid droplets, suggesting that the P protein may 
play a role in binding to viral RNA within IBs to facilitate replication and transcription 
(FIG 4.3B). 
HMPV P recruits N0-P to liquid droplets 
 
WT HMPV N spontaneously oligomerizes and binds to nonspecific RNAs 
during standard purification procedures. Thus, we generated a recombinant N0-P 
construct that includes full-length N (1-394) fused to a P peptide (1-40) to maintain 
N in a monomeric, RNA-free form for purified protein analysis (FIG 4.4A) (47). Like 
our approach with HMPV P, the N0-P construct was purified by two different 
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methods to assess the effects of nucleic acid contaminants on our in vitro LLPS 
system. The first procedure included an IMAC purification, and the alternative 
procedure included both IMAC and heparin purification steps. Though the N0-P 
protein purified by IMAC alone contained few protein contaminants, we were able 
to successfully reduce the nucleic acid level with the addition of a heparin 
purification step, as indicated by the A260/280 ratio of 0.6. 
The N0-P construct purified by IMAC alone formed gel-like droplets that 
were visualized by DIC microscopy (FIG 4.4B). Unlike the HMPV P liquid droplets, 
the gel-like HMPV N0-P droplets remained partially undissolved in high salt 
concentrations (data not shown). Over time, these gel-like droplets aggregated 
together but did not undergo fusion (FIG 4.4B). In agreement with our microscopy 
results, turbidity assays performed with the IMAC purified N0-P protein gave high 
absorbance readings that peaked above 0.6, further indicating that the gel-like 
droplets were aggregating in solution (FIG 4.5C). The subsequent drop in 
absorbance suggests that the gel-like droplets settled to the bottom of the 96-well 
plate. 
The N0-P construct was tested with anion exchange purified HMPV P using 
a droplet assay to determine if the P protein could influence N0-P dynamics in 
solution. Our DIC and fluorescence microscopy analyses showed that mixing the 
two constructs together led to enhanced LLPS as indicated by the presence of 
larger and more numerous droplets than we previously observed for HMPV P 
alone. The results showed that N0-P and P were incorporated into the same liquid 
droplets, as indicated by the colocalization of the fluorescent signals used to label 
the proteins (FIG 4.5A). In addition, the phase separated droplets underwent fusion 
events (FIG 4.5B). A turbidity assay was utilized to determine if combining N0-P 
with P affected the absorbance of the solution. The results showed that compared 
to N0-P alone, the combination of N0-P and P led to lower absorbance readings 
that peaked around 0.3 at two hours (FIG 4.5C). Together, these findings support 
that HMPV P facilitates interactions with N0-P to recruit the protein into liquid 
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droplets, and interactions between the proteins prevent the N0-P construct from 
transitioning to a gel-like state. 
The N0-P construct that was alternatively purified by IMAC and heparin was 
also analyzed using our in vitro system. Unlike the N0-P protein purified by IMAC 
alone, the heparin purified N0-P formed liquid droplets in the absence of other 
protein binding partners (FIG 4.6A). Time lapse imaging of the heparin purified N0- 
P droplets showed that they could fuse to form larger droplets (FIG 4.6B). Since 
the removal of contaminating nucleic acids had a dramatic effect on N0-P LLPS 
dynamics, we tested the heparin purified N0-P with a fluorescent RNA oligomer to 
determine if the addition of nucleic acid would influence droplet formation. 
Fluorescence microscopy imaging showed that the RNA oligomer disrupted N0-P 
liquid droplet formation, leading to the formation of non-fusing aggregates (FIG 
4.6C). These results suggest that RNA interactions inhibit N0-P LLPS dynamics, 
causing the liquid droplets to transition to a gel-like or solid-like state. 
HMPV P recruits N-RNA rings to liquid droplets 
 
In addition to the monomeric N0-P construct, WT N-RNA rings were purified 
for LLPS analysis in the presence or absence of HMPV P. DIC imaging of N-RNA 
rings in the droplet assay showed the formation of aggregates, suggesting that this 
protein-RNA complex does not phase separate independently (FIG 4.7A). 
Combining the purified N-RNA rings with heparin purified HMPV P resulted in the 
N-RNA complex being incorporated into liquid droplets (FIG 4.7B). The N-RNA/P 
droplets (maximum droplet size = 6 µm) were generally smaller than the P alone 
droplets (maximum droplet size = 11 µm), suggesting that this combination 
influences phase separation dynamics. The influence of HMPV P on N-RNA for 
liquid droplet formation was reflected in the turbidity assay results which showed 
a lower peak for absorbance around 0.2 at two hours, compared to the absorbance 
for N-RNA alone (FIG 4.7D). 
HMPV P and N-RNA were tested in our in vitro system at different ratios to 
determine the conditions that were required for N-RNA to be recruited to liquid 
droplets. Though N-RNA aggregates were still present at 4:1 and 2:1 ratios of N- 
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RNA/P, liquid droplets were easily detected at a 1:1 ratio. The number and size of 
the liquid droplets increased in samples with a higher proportion of HMPV P (1:2 
and 1:4) (FIG 4.7C). These results suggest that a minimum threshold for the P 
protein concentration must be met before N-RNA is induced to phase separate into 
droplets. Liquid droplets containing HMPV P and N-RNA were also shown to 
incorporate a fluorescent RNA oligomer (FIG 4.7E). These findings highlight that 
HMPV P, N, and RNA form complex multivalent interactions to promote phase 






IB formation has been reported for many negative-strand viruses across 
different families in the Mononegavirales order (148). An increasing wealth of 
evidence supports that these structures function as viral factories by concentrating 
the machinery and materials required for replication and transcription. Cellular 
studies of IBs have shown that these structures are membrane-less and dynamic, 
which led to the characterization of IBs as liquid organelles. Though liquid 
organelles have been recognized in the cell for many decades, scientists have only 
recently linked the formation of these structures to the biophysical process of 
LLPS. Understanding the role of LLPS in IB formation may be critical for 
discovering new targets for antiviral development. Until now, no reports have been 
published to identify HMPV IBs as phase separated liquid organelles. To analyze 
the viral protein interactions driving this process, an in vitro system was utilized to 
test recombinant versions of HMPV purified proteins. 
We focused on purifying full-length P, N-RNA rings, and the monomeric N0- 
P construct for in vitro analysis. Though the process of IB formation likely involves 
many similarities for different negative-strand viruses, our analysis of HMPV 
proteins led to the discovery of unique features that highlight differences among 
these viral systems. We found that HMPV P phase separates independently in 
vitro, supporting our hypothesis that the P protein is a scaffold which recruits other 
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client proteins to liquid droplets to drive LLPS. Interestingly, our data also showed 
that HMPV P incorporates RNA into liquid droplets. This suggests that the P 
protein, which is known to bind several proteins involved in the replication process, 
may also directly interact with RNA to facilitate phase separation and to enhance 
viral replication. In addition to incorporating RNA, purified HMPV P also recruited 
monomeric N0-P and oligomeric N-RNA rings to liquid droplets, further supporting 
our model in which P serves as a scaffold for LLPS. This is the first report to 
highlight a negative-strand virus P protein as the independent driver of phase 
separation. Additionally, this work provides the first evidence for a previously 
undescribed role of HMPV P for interacting directly with RNA. Together, these 
findings provide important information for understanding the formation of HMPV 
IBs that may be applicable to other negative-strand viruses. 
Our previous studies of HMPV IBs showed that these structures contain 
viral positive-sense RNA and genomic RNA along with the N and P proteins. 
However, other viral proteins, such as the fusion protein and matrix protein, are 
generally excluded from IBs (56). The contents of HMPV IBs suggested that these 
structures were likely involved in housing viral replication and transcription, 
whereas assembly steps appeared to occur outside of IBs. We highlighted that the 
cellular actin network plays a role in bringing small IBs together to form larger 
membrane-less structures. In addition, we confirmed that IB formation and 
coalescence is critical for promoting efficient replication and transcription (56). 
Other work from our lab has focused on late events in the HMPV life cycle to 
understand assembly and spread. Interestingly, the HMPV P protein was shown 
to extensively colocalize with actin and promote the formation of cellular 
extensions for direct cell-to-cell spread of infection (76). A recent report from our 
group utilizing three-dimensional human airway tissues to study HMPV infection 
supported these findings related to viral replication and spread. HMPV-infected 
human airway epithelial (HAE) cells showed the presence of IBs containing N 
protein, P protein, and viral genomic RNA (149). Additionally, the HMPV-infected 
HAE cells were shown to form actin-based filamentous extensions (149). These 
results suggested that IB and extension formation are physiologically relevant 
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processes used by HMPV to promote infection. HMPV extensions may provide a 
route for transporting IB components to new cells to expedite the infection process. 
The liquid-like nature of IBs may be critical for moving infectious materials through 
narrow cell-to-cell extensions. 
We hypothesized that the intrinsically disordered regions of HMPV P allow 
it to interact with a variety of proteins to promote IB formation. Recently, a structure 
was published for the HMPV polymerase/P protein complex (92). The cryo- 
electron microscopy structure showed that the P protein tetramer interacts 
extensively with the N-terminal region of the polymerase. The central 
oligomerization domain of HMPV P is anchored to the polymerase, and the N- 
terminal regions of P undergo a disorder-to-order transition upon binding to N0 
(47). HMPV P may facilitate delivery of N0 to the RNA exit tunnel to encapsidate 
nascent RNA. The C-terminal regions of P are asymmetrically oriented on the 
polymerase to promote interactions with N-RNA, likely to dislodge the RNA and 
deliver it to the entrance of the polymerase RNA tunnel (47, 92). The non- 
equivalent positions of the HMPV P C-terminal regions within the tetramer highlight 
the importance of IDRs, which allow a protein to adopt a variety of conformations 
(150). Like HMPV P, RSV P is also a tetrameric protein with a central 
oligomerization domain flanked by long IDRs (151-154). A structure of the RSV 
polymerase/P protein complex was published around the same time as the HMPV 
structure. The RSV structure showed that each protomer of the P protein tetramer 
adopts a different conformation in association with the polymerase (155). Similar 
to HMPV, these results highlight the dynamic nature of the P protein which is 
heavily influenced by the presence of large IDRs. Though some structural aspects 
of P proteins differ among negative-strand RNA viruses, IDRs are a common P 
protein feature across families (84, 90, 95, 145, 153, 154, 156, 157). 
Features of HMPV P and other negative-strand virus P proteins, including 
long IDRs, repetitive blocks of alternating charge, and phosphorylation sites, fit the 
molecular signature of proteins that phase separate under physiological conditions 
(83, 84). The propensity for HMPV P to mediate multivalent interactions and phase 
74  
separate independently in vitro suggests that it functions as a scaffold to regulate 
LLPS for IB formation during infection (80). In contrast to our in vitro results, the 
HMPV N and P proteins must be coexpressed in cells to generate IB-like structures 
(65). Without HMPV N, the P protein shows diffuse cytoplasmic localization. This 
difference between the cellular and in vitro systems suggests that host factors 
present in the cytoplasm may block HMPV P interactions required to induce LLPS. 
However, coexpression of HMPV P and N likely creates more opportunities for 
multivalent protein-protein and protein-RNA interactions to concentrate enough IB 
components to drive phase separation. LLPS is a highly sensitive process that 
depends on a number of factors such as protein/RNA concentration, salt content, 
pH, and temperature (83). Thus, one or more of these factors in cells may prevent 
HMPV P from phase separating when expressed on its own. Our findings highlight 
notable contrasts between cellular and in vitro studies of HMPV IBs, suggesting 
that in vitro work must be carefully analyzed before applying conclusions to live 
virus systems. Though cellular and in vitro IB studies are both crucial for 
understanding HMPV replication, further analysis is needed to bridge the gap 
between these bodies of work. 
Reports on MeV and RSV IBs have utilized a similar in vitro system to 
analyze phase separation dynamics of purified proteins (87, 88). MeV IBs were 
first characterized as liquid organelles by analyzing the structures in infected or 
transfected cells (86). Analysis of MeV IBs during infection showed that the 
structures are initially spherical, but they become large and irregularly shaped at 
later time points of infection. In transfected cells, MeV N and P are sufficient to 
mediate IB-like structure formation, with the C-terminal domains of both proteins 
being critical for phase separation. However, MeV P expression alone induced the 
formation of perinuclear puncta, which were rarely spherical and very large, in 35 
percent of transfected cells. This suggests that MeV P may promote multivalent 
interactions under specific cellular conditions to form these structures (86). MeV in 
vitro studies showed that a combination of the N and P proteins was required to 
induce droplet formation. The minimum N and P domains needed for droplets to 
form were also reported: full-length N protein bound to a 50 amino acid N-terminal 
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P peptide (P50) and P304-507, which includes the tetramerization domain, intrinsically 
disordered Ploop, and C-terminal three-helix bundle (XD) (87). Contrasting LLPS 
results observed for MeV and our HMPV system may be due to differences in the 
P protein structures. For instance, MeV P is 213 amino acids longer than HMPV P 
and includes the folded XD domain after the unfolded Ploop. 
A recent report on RSV used both cellular and in vitro analysis to 
characterize RSV IBs as liquid organelles formed via LLPS. Deletion of the N- 
terminal IDR of RSV P did not impact IB-like structure formation in cells, but the 
oligomerization domain and C-terminal IDR were required (88). This was 
supported by in vitro results which showed that the N-terminal domain was 
dispensable, but the C-terminal domain and oligomerization domain were required 
for liquid droplet formation with N-RNA. They also showed that a higher ratio of 
RSV P to N-RNA was needed to detect liquid droplet formation, whereas we 
observed that HMVP N-RNA/P droplets were easily detected at a 1:1 ratio (88). 
Compared to HMPV P, RSV P is 53 amino acids shorter, though the domain 
organization is similar for both. The differences observed for these viral systems 
highlight that LLPS is highly dependent on multivalent interactions mediated by the 
P protein, and these interactions are influenced by the unique composition of the 
P protein. Additional analysis of specific HMPV N and P protein domains will be 
beneficial for determining which domains are critical for phase separation and IB 
formation. 
The RSV and MeV reports also analyzed the importance of interactions 
between the N protein and RNA for LLPS. An RNA-binding mutant of MeV N still 
formed IB-like structures with P protein in cells, suggesting that N/RNA interactions 
are not required for IB formation (86). The minimal MeV LLPS in vitro system was 
also used to show that RNA diffuses into MeV N/P liquid droplets, triggering the 
formation of nucleocapsid-like particles (87). The rate of particle assembly was 
significantly increased compared to non-phase separating conditions. These 
findings suggest that RNA is not required for N/P droplet formation, but IBs serve 
to enhance the efficiency of nucleocapsid assembly during infection. Incorporation 
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of RNA into HMPV P droplets in our system highlights that HMPV may utilize IB 
formation in a similar manner to facilitate nucleocapsid assembly. A monomeric, 
RNA-free RSV N protein mutant was unable to form IB-like structures with WT P 
protein in cells, suggesting that RSV N must oligomerize and bind RNA to mediate 
IB formation (88). However, our in vitro results with HMPV N0-P suggested that 
oligomerization and RNA interactions are not required for phase separation. An in 
vitro analysis of HMPV and RSV N RNA-binding mutants would be useful for 
further analyzing the role of RNA interactions and oligomerization in LLPS. Though 
the structures of RSV N and HMPV N are quite similar, small differences may have 
a dramatic impact on the weak multivalent interactions with HMPV P that drive 
LLPS. 
In conclusion, we showed that HMPV P acts as a scaffold for in vitro phase 
separation to recruit monomeric N protein, oligomerized N protein, and RNA to 
liquid droplets. These results support our cellular analysis of HMPV IBs, in which 
we have described IBs as dynamic, membrane-less structures that coalesce 
throughout infection. These findings support the hypothesis that many negative- 
strand viruses of the Mononegavirales order have evolved mechanisms to utilize 
LLPS for IB formation to promote efficient replication and transcription. Our results 
support that the large IDRs of HMPV P allow for the protein to phase separate 
independently and recruit other proteins to liquid droplets. Research from our lab 
has shown that HMPV P is phosphorylated in cells (Thompson, unpublished data). 
Phosphorylation and other post-translational modifications have been shown to 
play a role in phase separation. Thus, additional in vitro and cellular studies of 
HMPV P will be important for elucidating the effects of phosphorylation and 
dephosphorylation events. Work on HMPV should also continue to define the 
domains of the N and P proteins required for phase separation. Finally, further 
work on HMPV P to understand how it recruits RNA to liquid droplets will be critical 
for characterizing its role in LLPS. Overall, the findings presented here build on the 
foundation for understanding the formation of IBs and the mechanisms that 









Figure 4.1 Anion exchange purified HMPV P phase separates independently 
in vitro. (A) Anion exchanged purified HMPV P was tested at concentrations 
ranging from 5 µM to 50 µM in a droplet assay (maximum droplet size = 3.4 µm). 
DIC microscopy imaging of droplets was performed with a 60X objective on a 
Nikon Eclipse E600. The scale bar is 10 µm. (D) Time lapse imaging of anion 
exchange purified HMPV P (80 µM) droplet fusion was acquired using a 100X oil 
objective on a Zeiss Axiovert 200M microscope. (C) Anion exchange purified 
HMPV P (40 µM) was mixed with turbidity assay buffer in a clear 96-well plate. The 
solution was analyzed using a SpectraMax iD3 to measure the absorbance at 395 





Figure 4.2. Heparin purified HMPV P phase separates independently in vitro. 
(A) Heparin purified HMPV P was tested at concentrations ranging from 5 µM to 
50 µM in a droplet assay (maximum droplet size >50 µm). DIC microscopy imaging 
of droplets was performed with a 60X objective on a Nikon Eclipse E600. The scale 
bar is 10 µm. (B) Time lapse imaging of heparin purified HMPV P (150 uM) droplet 
fusion was acquired using a 100X oil objective on a Zeiss Axiovert 200M 
microscope. (C) Heparin purified HMPV P (40 µM) was mixed with turbidity assay 
buffer in a clear 96-well plate. The solution was analyzed using a SpectraMax iD3 




Figure 4.3. Interactions with nucleic acid modulate HMPV P phase separation 
dynamics. (A) Anion exchange purified HMPV P (15 µM) and heparin purified 
HMPV P (15 µM) were tested in a droplet assay using buffers with different 
concentrations of KCl ranging from 0 mM to 500 mM. DIC microscopy imaging of 
droplets was performed with a 60X objective on a Nikon Eclipse E600. The scale 
bar is 10 µm. (B) Heparin purified HMPV P (15 µM) was tested in a droplet assay 
with an RNA decamer tagged with 6-carboxyfluorescein on the 3’ end (5 µM). The 
DIC and fluorescence images were acquired with a 60X objective on a Nikon 




Figure 4.4 IMAC purified N0-P forms gel-like droplets that aggregate over 
time. (A) Schematic of the N0-P construct which includes full-length HMPV N fused 
to the first 40 amino acids of HMPV P. (B). IMAC purified HMPV N0-P (15 µM) 
labeled with Alexa 488 TFP ester was tested in a droplet assay. DIC and 
fluorescence images were acquired at different time points using a 60X objective 




Figure 4.5. HMPV P recruits N0-P to liquid droplets. (A) IMAC purified HMPV 
N0-P (15 µM) labeled with Alexa 488 TFP ester was mixed with anion exchange 
purified HMPV P (15 µM) labeled with Alexa 594 NHS ester in a droplet assay. 
Fluorescence images were acquired using a 60X objective on a Nikon Eclipse 
E600. The scale bar is 10 µm. (B) IMAC purified HMPV N0-P (50 µM) was mixed 
with anion exchange purified HMPV P (50 µM). Time lapse imaging of N0-P/P 
droplet fusion was acquired using a 100X oil objective on a Zeiss Axiovert 200M 
microscope. (C) IMAC purified HMPV N0-P (40 µM) was tested alone or with anion 
exchange purified HMPV P (40 µM) in a turbidity assay. The protein solutions were 
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plated in a clear 96-well plate with turbidity assay buffer, and the absorbance was 





Figure 4.6. Heparin purified HMPV N0-P phase separates independently in 
vitro. (A) Heparin purified HMPV N0-P was tested at concentrations ranging from 
5 µM to 50 µM in a droplet assay. DIC microscopy imaging of droplets was 
performed with a 60X objective on a Nikon Eclipse E600. The scale bar is 10 µm. 
(B) Time lapse imaging of heparin purified HMPV N0-P (80 µM) droplet fusion was 
acquired using a 100X oil objective on a Zeiss Axiovert 200M microscope. (C) 
Heparin purified HMPV N0-P (15 µM) was tested in a droplet assay with an RNA 
decamer tagged with 6-carboxyfluorescein on the 3’ end (5 µM). The DIC and 
fluorescence images were acquired with a 60X objective on a Nikon Eclipse E600. 




Figure 4.7. HMPV P recruits N-RNA rings to liquid droplets. (A) HMPV N-RNA 
(25 µM) was tested in a droplet assay. DIC microscopy imaging of droplets was 
performed with a 60X objective on a Nikon Eclipse E600. The scale bar is 10 µm. 
(B) HMPV N-RNA (15 µM) was mixed with heparin purified HMPV P (15 µM) in a 
droplet assay. DIC images were acquired using a 60X objective on a Nikon Eclipse 
E600. The scale bar is 10 µm. (C) HMPV N-RNA and heparin purified HMPV P 
were tested in a droplet assay at different ratios (4:1 = 20 µM N-RNA: 5 µM P; 2:1 
= 10 µM N-RNA: 5 µM P; 1:1 = 5 µM N-RNA: 5 µM P; 1:2 = 5 µM N-RNA: 10 µM 
P; 1:4 = 5 µM N-RNA: 20 µM P). DIC microscopy imaging of droplets was 
performed as described above. (D) HMPV N-RNA (40 µM) was tested alone or 
with heparin purified HMPV P (40 µM) in a turbidity assay. The protein solutions 
were plated in a clear 96-well plate with turbidity assay buffer, and the absorbance 
was measured at 395 nm by a SpectraMax iD3 at 5 min intervals with mixing. (E) 
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HMPV N-RNA (15 µM), heparin purified HMPV P (15 µM), and an RNA decamer 
tagged with 6-carboxyfluorescein on the 3’ end (5 µM) were mixed and tested in a 
droplet assay. DIC and fluorescence microscopy imaging of droplets was 
performed as described above. The scale bar is 10 µm. 
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The work presented here builds on our current understanding of viral fusion 
events, replication, and inclusion body (IB) formation for viruses within the 
Mononegavirales order. Specifically, these findings elucidate previously unknown 
aspects of the viral life cycle for paramyxoviruses and pneumoviruses. Many 
studies on viral entry have focused on the membrane glycoprotein that promotes 
fusion with a target cell membrane. Cellular protein experiments and structural 
analysis of viral particles and proteins have provided a platform for determining the 
conformational changes in the glycoprotein that regulate the fusion event. Our 
group has focused its work on the transmembrane domain (TMD) of the Hendra 
virus (HeV) fusion protein (F) to determine how interactions in this region regulate 
fusion dynamics. We found that the TMDs of the HeV F trimer must dissociate to 
allow for conformational changes within the protein that lead to membrane fusion 
(Chapter 3). After analyzing this early step in the viral life cycle, we addressed 
questions regarding subsequent steps in the cycle that occur in the host cell 
cytoplasm. Many negative-strand viruses produce cytoplasmic IBs for replication 
and transcription, but numerous questions remain unanswered regarding how IBs 
form and function. We built on our previous work with human metapneumovirus 
(HMPV) to analyze the mechanisms regulating IB formation to understand how 
they promote replication and transcription. We discovered that the HMPV 
phosphoprotein (P) plays a critical role in mediating IB formation via the process 
of liquid-liquid phase separation (LLPS) (Chapter 4). These studies on HeV and 
HMPV shed light on the complex protein interactions that govern fusion protein 
triggering, IB coalescence, and replication/transcription events. In addition, they 




Determining HeV F TMD interactions 
Analysis of the HeV F TMD sequence is important for understanding the 
interactions that contribute to trimerization as well as dissociation once the F 
protein is triggered. One sequence motif that has been shown to enhance TMD 
interactions in different proteins is GXXXG. The HeV F TMD includes an AXXXG 
motif, and mutation of the glycine residue decreased cell surface expression, 
suggesting that prefusion HeV F stability was reduced (40). Sedimentation 
equilibrium analysis was also used to determine the effects of mutating this TMD 
glycine residue. The results showed that mutating the glycine to alanine led to a 
moderate increase in TMD interactions, whereas mutating glycine to leucine or 
isoleucine led to even stronger TMD association (40). This suggested that the 
G508 residue was not the only factor driving TMD interactions in HeV F, since 
other residues must be responsible for maintaining the F protein trimer. Further 
work addressed the presence of polar residues in the TMD because cooperative 
interaction of polar residues has been associated with transmembrane helix 
packing. Mutation of HeV F TMD polar residues to alanine showed that protein 
folding was impacted and stability was reduced, suggesting that these polar 
residues are required for proper TMD interactions (40). 
In addition to stabilizing the prefusion conformation, some HeV F TMD 
residues are important for endocytic recycling. This process is crucial so that the 
precursor F0 can be cleaved to form the disulfide-linked heterodimer F1+F2, which 
can actively participate in fusion events. Compared to other TMDs, the HeV F TMD 
contains many noncharged polar residues (158). Two polar amino acids, S490 and 
Y498, in the HeV F TMD were shown to be important for proper HeV F trafficking. 
S490, which sits close to the ectodomain of HeV F in the N-terminal region of the 
TMD, is important for HeV F endocytosis. Specifically, the serine hydroxyl group is 
required for proper trafficking. Hydrogen bonds between this hydroxyl group and 
other side chains likely influence this process. Y498 is required for efficiently 
recycling HeV F to the surface after processing, and the aromatic ring, rather than 
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the hydroxyl group, promotes the interactions which allow for this event (28). The 
S490 and Y498 residues are also found in the TMD of the Nipah virus (NiV) F 
protein, suggesting that they are crucial for NiV F endocytosis and recycling events 
as well (28). This work further expanded our understanding of the importance of 
TMD interactions for critical HeV F functions. 
The sequence of the HeV F TMD was compared to other paramyxovirus F 
protein TMD sequences to analyze similarities that could govern TMD interactions. 
Evaluation of 140 sequences led to the identification of a β-branched heptad 
repeat. Specifically, the HeV F TMD was shown to possess a heptad repeat 
leucine-isoleucine zipper, a motif which promotes oligomerization in a hydrophobic 
environment (114). Mutation of the leucine-isoleucine zipper reduced stability of 
the HeV F prefusion conformation. This suggests that TMD interactions promoted 
by the leucine-isoleucine zipper are required to maintain the metastable prefusion 
structure. In addition, results from this study suggested that TMD interactions play 
a significant role in the triggering process (114). The leucine-isoleucine zipper 
identified in the parainfluenza virus 5 (PIV5) F TMD was also mutated to determine 
the effects on F protein expression, stability, and fusion (159). Unlike HeV F, the 
mutations in the PIV5 F TMD only had modest effects on protein expression and 
stability. However, the PIV5 F TMD leucine-isoleucine zipper was critically 
important for fusogenic activity (159). Together, the work on HeV F and PIV5 F 
support the findings described in Chapter 3, which emphasize the significance of 
modulating TMD interactions to drive fusion. Overall, these findings highlight the 
dynamic TMD interactions which impact the F protein as it folds, traffics, undergoes 
processing, and triggers. 
Targeting the viral F protein TMD 
 
Though structural studies of HeV F and other F proteins have provided 
crucial conformational data, cellular expression studies are particularly important 
for further understanding the non-static conformational changes involved in F 
protein triggering. The work presented in Chapter 3 supports previous studies 
which showed that the TMD of HeV F has functional importance beyond anchoring 
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the protein in the viral membrane (41, 114). Specifically, the HeV F TMD 
interactions are required to stabilize the prefusion form prior to triggering, and 
changes in TMD interactions helps drive conformational refolding required for 
fusion. In addition, work on enveloped virus F proteins has shown that substituting 
the TMD region of one F protein into another can be detrimental for fusion activity, 
further suggesting that TMD interactions play a specific role in promoting fusion 
(160). Disrupting or prematurely triggering F proteins presents a potential 
therapeutic target that could be applicable to numerous enveloped viruses. 
Additional work was performed by our group to elucidate the role of TMD 
interactions in HeV F conformational stability. Exogenous transmembrane 
constructs mimicking the TMD of HeV F were expressed to determine if they could 
disrupt TMD interactions in wild type (WT) HeV F (161). Results showed that the 
transmembrane protein constructs reduced HeV F expression and fusion activity. 
This concept was also applied to the paramyxovirus PIV5 to see if homologous 
transmembrane constructs could block viral infection. Pretreatment of the virus 
with the PIV5 TMD construct led to reduced viral infection in cells (161). This 
suggests that TMD constructs or other peptides may be useful for targeting F 
proteins to cause them to misfold or prematurely trigger. Further studies on 
enveloped virus F proteins will be important for developing new therapies like this. 
The role of the TMD in HeV F conformational changes 
 
Work focused on TMD interactions and targeting the TMD has suggested 
that this region of the HeV F protein is critical for numerous functions, including 
fusogenic activity. To understand the factors that contribute to fusion events, we 
considered the TMD interactions that might promote conformational changes in 
the rest of the protein. The HeV F HRB forms a trimeric coiled coil, but isolated 
HRB peptides do not associate together (162). This suggests that HeV F TMD 
interactions are required to maintain the conformation of the HRB coiled coil prior 
to triggering. Interactions in the ectodomain may also help to preserve the spring- 
like HRB coiled coil. Our model, which is supported by data in Chapter 3, suggests 
that triggering of HeV F involves dissociation of the TMDs. TMD dissociation likely 
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modulates interactions within the HRB coiled coil, leading to further refolding of the 
ectodomain. Dissociation of the TMDs is suggested to begin with the C-terminal 
region where β-branched residues destabilize the alpha-helix (41). This localized 
dissociation may then initiate separation of N-terminal TMD regions and 
subsequently destabilize the HRB coiled coil. 
In Chapter 3, we analyzed HeV F TMD mutants which were chemically 
linked by disulfide bonds to prohibit dissociation of the TMD trimer. The double 
cysteine substitutions were made at the N-terminal region of the TMD to promote 
disulfide bond formation within the oxidizing environment of the endoplasmic 
reticulum. Our results suggest that TMD dissociation was not necessary for proper 
folding or trafficking of HeV F. However, fusion activity was completely abolished 
for the mutants, suggesting that TMD dissociation is required for refolding of HeV 
F. These findings support that TMD dissociation, which likely initiates at the C- 
terminal residues, must subsequently occur in the N-terminal TMD to allow for 
fusion. Since the N-terminal TMD region is connected to the HRB domain, 
dissociation of the N-terminal TMD residues may be the critical event which 
immediately precedes destabilization of the HRB coiled coil. Further studies will 
address the role of the N-terminal TMD residues in HeV F stability, trafficking, and 
fusogenic activity. 
The disulfide-linked HeV F TMD mutants were also tested with a prefusion 
conformation-specific antibody, and results showed that cell lysis led to decreased 
binding of the antibody, similar to WT HeV F which is triggered during cell 
disruption. This suggests that the mutants were not locked in the prefusion 
conformation and underwent some conformational changes. However, the 
conformations adopted by the mutants due to cell lysis are unclear. Cell lysis may 
alter interactions in the ectodomain, and the changes may be sufficient to 
destabilize the HRB coiled coil without the need for TMD dissociation. Future work 
should analyze the mutants to determine which conformational intermediates are 
able to form when the TMDs are locked together. These studies will be important 
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Phase separation for viral replication 
 
Phase separation of liquid organelles: Function and dysfunction 
 
Identification of IBs and other membrane-less compartments as phase 
separated condensates has generated many studies to understand how these 
structures are regulated. Researchers are particularly interested in the functions 
that emerge from organizing molecules into phase separated regions. For 
instance, reports have shown that disruption of condensates does not usually 
impact cell viability (80). However, the ubiquity of condensates in cells suggests 
that they serve an important functional role (80, 83, 163, 164). For HMPV, 
disruption of actin polymerization inhibited IB coalescence, leading to decreased 
viral expression. However, expression was not completely abolished (56). In the 
viral life cycle, any decrease in efficiency can be detrimental for the virus as it 
combats the host cell immune system to produce new viral progeny. This idea 
suggests that condensate formation may provide subtle enhancements in the 
frequency of biochemical reactions which together benefit the overall function of 
the cell or the invading pathogen. 
Researchers have also been interested in LLPS and condensates due to 
their role in neurodegenerative disease. Several proteins that are known to phase 
separate have been shown to form pathological brain inclusions, leading to various 
forms of neurodegeneration. One example is TDP-43, a stress granule protein 
involved in mRNA processes such as splicing, transport, and translation regulation. 
TDP-43 brain inclusions have been linked to a number of diseases including 
Alzheimer’s, amyotrophic lateral sclerosis (ALS), and chronic traumatic 
encephalopathy (165). Stress granules are known to form under certain conditions 
and dissociate when the stressor is removed. TDP-43 and other stress granule 
proteins can have pathological effects when mutations prevent disassembly of the 
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condensates. When liquid organelles lose dynamicity and transition to a solid-like 
state, they are generally unable to facilitate normal biochemical processes for the 
cell. Continued research into LLPS of liquid organelles is critical to understand how 
changes in protein-protein and protein-RNA interactions can drive condensates to 
transition to an aggregated, solid-like state. This work may also impact our 
knowledge of viral IB formation, since HMPV P modulates interactions with N-RNA, 
which aggregates in solution, to incorporate it into liquid droplets. Determining the 
mechanisms that drive phase transitions in liquid organelles and pathological 
inclusions will provide critical knowledge for understanding the links between LLPS 
and biomolecular condensates. 
Maturation of IBs during infection 
 
Though pathological inclusions transition to a solid-like state, it is normal for 
condensates to mature over time due to their metastable nature (165). 
Thermodynamically, larger droplets are more stable than smaller droplets, so 
smaller droplets spontaneously dissolve as proteins diffuse into larger droplets. 
This event, which is known as coarsening, is different from fusion events which 
involve two smaller droplets coming together to form a larger droplet (165). As 
coarsening occurs over time, droplets become less dynamic and mature to a gel- 
like state. This process is thought to be driven in part by proteins with intrinsically 
disordered regions (IDRs). Compared to pathological aggregates, which undergo 
a rapid transition to a solid-like state, this maturation process is much slower and 
can be reversed (165). A physical explanation for droplet maturation is interesting 
in the context of viral IBs. 
The liquid nature of IBs was initially described for rabies virus (RABV) Negri 
bodies (66). RABV Negri bodies have been shown to incorporate a variety of 
proteins including the P protein, nucleoprotein (N), polymerase, and matrix protein 
(72, 166). In addition, the host proteins Hsp70 and focal adhesion kinase (FAK) 
localize to Negri bodies (167, 168). Interestingly, FAK was shown to directly 
interact with RABV P, and disruption of this interaction inhibited viral RNA 
replication and viral protein expression (168). The Hsp70 chaperone directly 
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interacts with RABV N and is suggested to be involved in viral transcription or 
translation (167). These findings highlight the complex composition of Negri bodies 
and their role in promoting efficient viral multiplication. Negri body formation was 
characterized over time during RABV infection, and results showed that the 
spherical structures grew over time and sometimes evolved into irregular shapes 
(66). The later stage, nonspherical Negri bodies were often associated with 
membranes. Observations of changes in the number, size, and shape of RABV 
Negri bodies suggests that these liquid organelles undergo a maturation process 
throughout infection. Characterizing the mechanisms that regulate Negri body 
maturation will be important for illuminating their role in the viral life cycle. 
Maturation of measles virus (MeV) IBs has also been observed during 
infection (86). Until 12 hours post infection, MeV-infected cells showed the 
presence of small spherical structures in the cytoplasm. At later time points, larger 
IBs were observed, and some were irregularly shaped. The nonspherical 
structures were often located near the nucleus (86). The irregular shape of later 
stage IBs suggests that they transition to a less dynamic state over time. Like 
RABV, the loss of spherical shape may be partly due an association with host cell 
membrane components at later points of infection. Many positive-sense RNA 
viruses are known to associate with membranes to generate replication complexes 
(169). Thus, some negative-strand RNA viruses may also utilize membrane 
components within IBs to enhance replication or another step of the viral life cycle. 
HMPV and RSV infections show differences in the maturation IBs. As 
HMPV infection progresses, the quantity of IBs was shown to modestly increase, 
with only a few IBs generally found in each cell at late infection time points (56). 
IBs tend to increase in size throughout infection, suggesting that they undergo 
fusion events and mature as more protein diffuses into the structures. Even at late 
time points, HMPV IBs typically retain a spherical shape, in contrast to the irregular 
structures observed for MeV and RABV. For RSV, IBs contain substructures 
known as IB-associated granules (IBAGs) (67). Newly synthesized viral mRNA and 
the M2-1 protein localize to IBAGs, whereas the N, L, and P proteins as well as 
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viral genomic RNA are excluded from these structures. These structures were 
shown to develop within IBs by 12 hours post infection, suggesting that they form 
as a result of IB maturation over time. IBAG formation within IBs was shown to be 
dependent upon viral mRNA synthesis (67). The findings for RSV IBs suggest that 
newly transcribed viral mRNAs are stored within IBAGs prior to release into the 
cytoplasm. However, further studies are needed to understand the function of 
IBAGs and the mechanisms that regulate maturation of these IB substructures. 
Thus far, IBAGs have not been observed for any other negative-strand RNA 
viruses. 
In vitro analysis of HMPV proteins showed that heparin purified HMPV P 
liquid droplets often contained round, dimple-like regions (FIG 5.1). In addition, 
these dimple-like regions were also observed for liquid droplets containing HMPV 
N-RNA and P (FIG 5.1). Additional analysis is needed to determine if the formation 
of these regions is functionally important to liquid droplet formation. However, it is 
interesting to speculate that HMPV proteins may induce interactions for LLPS that 
lead to the formation of IB substructures, similar to the IBAGs observed for RSV. 
Though the initial characterization of HMPV IB formation did not show the 
presence of IB substructures, high resolution microscopy techniques may be 
beneficial for identifying previously unrecognized features of IBs for different 
viruses. 
Liquid organelle maturation is also interesting in the context of the 
monomeric HMPV N0-P construct that was purified for in vitro studies. As described 
in Chapter 4, immobilized metal affinity chromatography (IMAC) purified HMPV N0- 
P formed gel-like droplets which did not undergo fusion. However, adding a 
heparin purification step allowed for N0-P to phase separate in the absence of other 
binding partners. This suggests that nucleic acid contaminants in the IMAC purified 
HMPV N0-P solution impact LLPS dynamics. Higher levels of nucleic acid may 
increase the rate at which N0-P droplets transition from a liquid to gel-like state. 
This is an interesting result since some viral IBs appear to become more gel-like 
at late stages of infection (86). As the level of RNA increases within IBs during 
replication and transcription, the RNA may drive the transition of IBs from liquid- 
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like to gel-like, leading to slower exchange of materials with the cytoplasm. 
However, this maturation to a gel-like state likely involves modulation of numerous 
factors in addition to RNA concentration. 
The role of RNA-binding in phase separation 
 
Different varieties of RNA-protein granules are a common example of liquid 
organelles found in the cell. The presence of viral genomic RNA and viral mRNA 
in IBs suggests that they possess similarities with other RNA-protein granules. In 
Chapter 4, we reported that HMPV P recruited monomeric, RNA-free N protein and 
oligomeric N-RNA rings to liquid droplets. This suggests that RNA interactions with 
N protein are not required for phase separation with HMPV P. MeV work showed 
that IB-like structures formed in cells when an N protein RNA-binding mutant was 
cotransfected with MeV P (84). Additionally, recombinant MeV N protein purified 
as a monomer phase separated with MeV P in vitro (87). However, RSV studies 
suggested that N protein oligomerization and RNA-binding were required for IB- 
like structure formation with RSV P in cells (88). These varying results warrant 
further work into the role of RNA-binding in viral protein phase separation. 
In addition to our monomeric N0-P construct, we also purified a potential 
HMPV N RNA-binding mutant, based on an RNA-free mutant described for RSV 
(170). The RSV mutant N K170A/R185A was purified as a monomer and was 
shown to lack the ability to bind RNA, based on the low A260/280 ratio of the 
purified protein. After sequence comparison with RSV N, we designed HMPV N 
K171A/R186A as a potential RNA-binding mutant to test in our purified protein 
system. The construct was prepared using an IMAC purification step followed by 
a heparin purification step. When HMPV N K171A/R186A was tested 
independently in the droplet assay, it formed aggregates similar to N-RNA and 
IMAC purified N0-P (FIG 5.2). Interestingly, HMPV N K171A/R186A was recruited 
to liquid droplets when it was mixed with anion exchange purified HMPV P (FIG 
5.2). This further supports that N RNA-binding is not required for phase separation 
of HMPV proteins. However, further experiments are needed to confirm that the N 
K171A/R186A mutations effectively block RNA-binding. Additionally, the HMPV 
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N0-P and N K171A/R186A constructs should be expressed in cells alone or with 
HMPV P to determine if IB-like structures form. These cellular results would be 
beneficial in conjunction with the in vitro purified protein data for explaining phase 
separation mechanisms. 
Along with the HMPV N K171A/R186A mutant, future studies will analyze 
other HMPV N constructs that possess mutations in the RNA-binding cleft. We are 
particularly interested in analyzing these mutants since RNA plays a significant 
role in phase separation (164, 171). The published structure of the HMPV N RNA- 
binding cleft was analyzed to select specific residues to mutate: K171A, R185A, 
R186A, R189A, and R341A (47). These mutants will be tested in the in vitro system 
and in cellular studies to determine their effects on viral replication and phase 
separation. A minigenome assay will be used to determine if these mutations block 
or inhibit replication. Immunofluorescence experiments will be utilized to assess 
whether the mutants form IB-like structures with HMPV P. For the mutants that do 
form IB-like structures, fluorescence recovery after photobleaching (FRAP) 
analysis will be performed to analyze the internal contents of the compartments. 
The FRAP results will be compared to the recovery observed for IB-like structures 
formed by WT HMPV N and P. 
The COVID-19 pandemic has generated an enormous amount of research 
focused on understanding the infectious mechanisms of the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), and some studies have 
highlighted the role of phase separation in the SARS-CoV-2 life cycle. SARS-CoV- 
2 is a positive-strand RNA virus with a large genome of approximately 30 
kilobases. It uses a multifunctional nucleoprotein (N) to package the genome into 
new virions. Unlike the negative-strand viruses described throughout this 
dissertation, SARS-CoV-2 does not have a separate P protein to act as a cofactor 
for the polymerase. Instead, the SARS-CoV 2 N protein contains three IDRs and 
is thought to facilitate viral RNA synthesis at early stages of infection. Several 
reports, many of which are still preprints, have reported that SARS-CoV-2 N forms 
condensates with viral RNA (172-176). This suggests that SARS-CoV-2 and other 
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coronaviruses may utilize LLPS to enhance viral replication and packaging. These 
findings support that viruses outside of the negative-strand RNA virus classification 
may have also evolved mechanisms to generate condensates to 
compartmentalize specific reactions. 
Post-translational modification of the P protein 
 
IDRs within proteins are particularly susceptible to post-translational 
modifications because they lack secondary structure (177). In general, post- 
translational modifications often act as switches to turn proteins on or off to 
regulate cellular events. Post-translational modification of intrinsically disordered 
proteins in liquid organelles provides another method by which cells can influence 
the formation and dissolution of these structures. One type of post-translational 
modification is phosphorylation of serine, threonine, and tyrosine residues. The 
addition of a negatively charged phosphoryl group to an uncharged amino acid 
may either promote or inhibit the formation of phase separated compartments 
(177). 
MeV P is phosphorylated at several sites, including S86 and S151 which 
are located in IDRs. These two sites are phosphorylated by casein kinase 2, and 
the phosphorylation status of the residues changes when MeV P binds to N (178, 
179). Mutating the serine residues or inhibiting casein kinase II led to a decrease 
in the size of IB-like compartments formed in cells, suggesting that phosphorylation 
of MeV P affects structural aspects of IB formation (86). Additionally, the vesicular 
stomatitis virus P protein has been shown to undergo phosphorylation events by 
cellular kinases, leading to changes in transcriptional activity (180). In a SARS- 
CoV-2 preprint, phosphorylation of the multifunctional N protein led to the formation 
of liquid-like droplets with RNA, whereas unmodified N protein formed gel-like 
droplets with RNA (181). This study hypothesized that unmodified SARS-CoV-2 N 
is required for nucleocapsid assembly, whereas phosphorylated N protein phase 
separates for viral genome processing. The HMPV P protein was analyzed by 
mass spectrometry to show that it is phosphorylated at residues 106, 148, 157, 
158, 168, 171, and 271 (92). Further studies of HMPV P phosphorylation will be 
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important for understanding the role of these post-translational modifications in 
replication and IB regulation. 
Identifying IB-resident proteins 
 
Although some viral and host factors within IBs have been discovered, 
further identification of IB components may help elucidate the mechanisms that 
govern IB formation and maturation. However, purification of IBs from infected cells 
presents challenges since IBs have a liquid nature and lack a physical barrier. 
Recent work described the purification of liquid-like granules containing FUS, a 
DNA- and RNA-binding protein implicated in ALS (182). FUS contains a low 
complexity domain that allows it to form multivalent interactions to mediate LLPS 
(183). Since HMPV and other negative-strand RNA viruses form liquid organelles 
similar to FUS, this purification procedure may be beneficial for analyzing the 
internal contents of IBs to identify protein interactions that mediate LLPS. Viral IBs 
appear to mature throughout infection, so IBs would need to be purified at different 
time points and analyzed separately to fully understand the landscape of these 
structures. Purified IBs would be subjected to mass spectrometry and proteomic 
analysis to identify proteins that reside in IBs. These studies would provide critical 
information for understanding which proteins are recruited to IBs at different times 
during infection. Additional analysis would be needed to determine the protein- 
protein interactions that lead to IB recruitment. The different aspects of liquid 
organelles described here highlight some of the interesting research questions 
which must be addressed to benefit our fight against negative-strand RNA viruses 
that cause human disease. 
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Figure 5.1. HMPV P and N-RNA/P liquid droplets contain round, dimple-like 
regions. Heparin purified HMPV P (15 µM) was tested alone or with HMPV N-RNA 
(15 µM) in a droplet assay. DIC microscopy images were acquired with a 60X 
objective on a Nikon Eclipse E600. The scale bar is 10 µm. 
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Figure 5.2. HMPV P recruits N K171A/R186A to liquid droplets. HMPV N 
K171A/R186A (15 µM) was mixed with anion exchange purified HMPV P (15 µM) 
in a droplet assay. DIC images were acquired using a 60X objective on a Nikon 
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ALS Amyotrophic lateral sclerosis 
CedPV Cedar virus 
CT C-terminal cytoplasmic tail 
CTD C-terminal domain 
ER Endoplasmic reticulum 
F Fusion protein 
FAK Focal adhesion kinase 
FP Fusion peptide 
FRAP Fluorescence recovery after photobleaching 
G Attachment protein 
HeV Hendra virus 
HMPV Human metapneumovirus 
HRA/HRB Heptad repeat A/B 
IB Inclusion body 
IBAG Inclusion body-associated granule 
IDR Intrinsically disordered region 
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L Large polymerase protein 
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M Matrix protein 
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P-bodies Processing bodies 
 
PIV5 Parainfluenza virus 5 
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SH Small hydrophobic protein 
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